Protocol Number:  ADCT -301-001 
 
Official Title:   A Phase 1 Adaptive Dose -Escalation Study to Evaluate the Tolerability, Safety,  
Pharmacokinetics, and Antitumor Activity of  ADCT -301 in Patients with  
Relapsed or Refractory Hodgkin Lymphoma and Non -Hodgkin Lymphoma  
 
Study ID: [REMOVED]  
 
Document Date:  04 January 2019  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019 Page 1 CLINICAL STUDY PROTOCOL  
IND: 121912 
EudraCT Number : 2015 ‐005272 ‐25 
A Phase 1 Adaptive Dose -Escalation Study to Evaluate the Tolerability, Safety, 
Pharmacokinetics, an d Antitumor Activity of ADCT -301 in Patients w ith 
Relapsed or Refractory Hodgkin Lymphoma and Non -Hodgkin Lymphoma  
PROTOCOL NO. :  ADCT- 301-001 
Sponsor:  ADC Therapeutics SA 
 
 
 
Sponsor Contact:   
 
 
Medical Monitor:   
 
 
 
 
 
Date of Original Protocol:  22 January 2015  
Date of Amendment  1: 17 April 2 015 
Date of Amendment 2 : 18 December 2015  
Date of Amendment 3 : 8 April 2016  
Date of Amendment 4:  8 November  2016  
Date of Amendment 5:  4 May 2017  
Date of Amendment 6:  31 August 2017  
Date of Amendment 7:  19 January  2018  
Date of Amendment 8:  31 October  2018  
Date of Amendment 9: 04 January 2019  
Confidentiality Statement 
All financial and nonfinancial support for this study will be provided by  
ADC Therapeutics  SA. The concepts and information contained in this document or generated during the study 
are considered proprietary and may not be disclosed in whole or in part without the express, written consent of 
ADC Therapeutics SA. The study will be conducted according to the  current version of  International Co uncil 
for Harmonisation  harmonised tripartite guideline E6, Good Clinical Practice.  

ADC Therapeutics ADCT-301 
ADCT-301-001 Protocol Amendment 9 
D a t e  o f  P r o t o c o l :  4  J a n u a r y  2 0 1 9             P a g e  2  Protocol Approval  Sponsor Signatory
Study Title: A Phase 1 Adaptive Dose-Escalation Study to 
Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma 
Protocol Number: ADCT-301-001 
Date of Original Protocol: 22 January 2015 
Date of Amendment 1: 17 April 2015 
Date of Amendment 2: 18 December 2015 
Date of Amendment 3: 8 April 2016 
Date of Amendment 4: 8 November 2016 
Date of Amendment 5: 4 May 2017 
Date of Amendment 6: 31 August 2017 
Date of Amendment 7: 19 January 2018 
Date of Amendment 8: 31 October 2018 
Date of Amendment 9: 04 January 2019 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 3  
Declaration of Investigator  
I have read and understood all sections of the protocol entitled “A Phase 1 Adaptive 
Dose -Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor 
Activity of ADCT -301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and 
Non-Hodgkin Lymphoma” and the accompanying Investigator Brochure .  
I agree to s upervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with Protocol Amendment 9, dated  04 January 2019, the current version of  
International  Council for Harmonisation (ICH) harmonised tripartite guideline E6: Good 
Clinical Practice and all applicable governmental regulations .  I will not make changes to the 
protocol before consulting with ADC Therapeutics SA or implement protocol changes 
without independent ethics committee approval except to eliminate an immediate risk to patient s.  I agree to administer study treatment only to patients  under my personal 
supervision or the supervision of a sub-Investigator. 
I will not supply the investigational drug to any person not authoriz ed to receive it .  
Confidentiality will be protected .  Patient identity will not be disclosed to third parties or 
appear in any study reports or publications. I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from ADC Therapeutics SA.  
 
   
 
   
Signature of Principal Investigator   Date  
 
 
 
   
Printed Name of Principal Investigator    
  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 4 Table of Contents  
Table of Contents ...................................................................................................................... 4  
List of Figures ........................................................................................................................... 8  
Protocol Synopsis...................................................................................................................... 9  
List of Abbreviations ............................................................................................................... 19  
1 Introduction .................................................................................................................... 21  
2 Study Rationale and Justification for Dose Level Selection .......................................... 23  
3 Study Objectives ............................................................................................................. 24  
3.1 Primary Objectives  .................................................................................................24  
3.2 Secondary Objectives  .............................................................................................24  
  
4 Investigational Plan and Patient Selection  ..................................................................... 25  
4.1 Study Design ..........................................................................................................25  
4.1.1  Dose Escalation and Determination of the Maximum Tolerated Dose 
(Part 1)  ......................................................................................................26  
4.1.2  Dose Expansion (Part 2) ...........................................................................26  
4.2 Selection of Study Population ................................................................................27  
4.2.1  Inclusion Criteria  ......................................................................................27  
4.2.2  Exclusion Criteria  .....................................................................................28  
5 Study Procedures ............................................................................................................ 31  
5.1 Procedures by Study Day .......................................................................................31  
5.1.1  Screening Period (Day –28 to –1) ............................................................31  
5.1.2  Day 1 (± 3 days) of Each Cycle ................................................................33  
5.1.3  Day 8 (± 1 day) of Each Cycle .................................................................34  
5.1.4  Day 15 (± 1 day) .......................................................................................35  
5.1.5  End of Treatment Visit  ..............................................................................36  
5.1.6  Long- term Follow -up ................................................................................37  
5.2 Withdrawal of Patients from the Study  ..................................................................37  
5.2.1  Reasons for Withdrawal/Discontinuation  .................................................37  
5.2.2  Handling of Withdrawals  ..........................................................................38  
5.2.3  Patient Replacements ................................................................................38  
6 Study Treatments  ............................................................................................................ 39  
6.1 Method of Assigning Patients to Treatment Groups ..............................................39  
6.2 Prophylactic Treatments for Hypersensitivity  .......................................................39  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 5 6.3 Treatments Administered  .......................................................................................40  
6.4 Dose Delays and Modifications  .............................................................................41  
6.5 Study Stopping Rules .............................................................................................42  
6.6 Identity of Investigational Product .........................................................................43  
6.6.1  ADCT -301 Drug Product ..........................................................................43  
6.7 Management of Clinical Supplies  ..........................................................................43  
6.7.1  Study Drug Packaging and Storage ..........................................................43  
6.7.2  Study Drug Accountability  .......................................................................44  
6.8 Overdose Management  ..........................................................................................44  
6.9 Treatment Compliance  ...........................................................................................44  
6.10  Concomitant Treatment  ..........................................................................................44  
6.10.1  Prohibited During Study ...........................................................................44  
6.10.2  Permitted During Study  ............................................................................45  
6.10.3  Diagnostic, Work-up, and Management of 
Polyradiculopathy/Guillain-Barré Syndrome ...........................................46  
7 Study Assessments and Procedures  ................................................................................ 47  
7.1 Efficacy Assessments .............................................................................................47  
7.2 Pharmacokinetic and Pharmacodynamic Assessments  ..........................................47  
7.3 Safety and Tolerability Assessments ......................................................................48  
7.3.1  Dose -Limiting Toxicities and Dose- Escalation Scheme  ..........................49  
7.3.1.1  Definition of Dose- Limiting Toxicities  ................................. 49  
7.3.1.2  Safety Oversight by the Dose Escalation Steering Committee ............................................................................................... 50
 
7.3.2  Adverse Events .........................................................................................51  
7.3.2.1  Definitions of Adverse Events  ............................................... 51  
7.3.2.2  Eliciting and Documenting Adverse Events .......................... 51  
7.3.2.3  Reporting Adverse Events  ..................................................... 52  
7.3.2.4  Assessment of Severity  .......................................................... 53  
7.3.2.5  Assessment of Causality  ........................................................ 53  
7.3.2.6  Follow-up of Patients Reporting Adverse Events .................. 53  
7.3.3  Pregnancy .................................................................................................54  
7.3.4  Clinical Laboratory Analy ses ...................................................................54  
7.3.4.1  Hematology ............................................................................ 54  
7.3.4.2  Biochemistry  .......................................................................... 54  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 6 7.3.4.3  Urinalysis ............................................................................... 54  
7.3.4.4  Additional Renal Function Studies ........................................ 55  
7.3.4.5  Additional Microbiological Serological studies  .................... 55  
7.3.5  Electrocardiograms  ...................................................................................55  
7.3.6  Physical Examination  ...............................................................................55  
7.3.7  Vital Sign Mea surements  ..........................................................................56  
7.3.8  Eastern Cooperative Oncology Group Performance Status ......................56  
7.4 Sample Handling, Storage, and Shipment .............................................................56  
8 Statistical and Analytical Plan  ........................................................................................ 58  
8.1 Safety Endpoints ....................................................................................................58  
8.2 Study Endpoints .....................................................................................................58  
8.2.1  Primary Endpoints ....................................................................................58  
8.2.2  Secondary Endpoints ................................................................................58  
  
8.3 Sample Size Calculations  .......................................................................................59  
8.4 Analysis Sets ..........................................................................................................59  
8.5 Description of Subgroups to be Analyzed .............................................................60  
8.6 Statistical Analysis Methodology  ..........................................................................60  
8.6.1  Efficacy Analysis ......................................................................................60  
8.6.1.1  Overall Response Rate  ........................................................... 60  
8.6.1.2  Duration of Response ............................................................ 60  
8.6.1.3  Overall Survival ..................................................................... 60  
8.6.1.4  Progression- Free Survival  ..................................................... 60  
8.6.2  Safety Analyses  .........................................................................................61  
8.6.2.1  Analyses of Adverse Events  .................................................. 61  
8.6.2.2  Clinical Laboratory Results  ................................................... 61  
8.6.2.3  Addi tional Safety Assessments  .............................................. 62  
8.6.3  Pharmacokinetic and Pharmacodynamic Analyses ..................................62  
8.6.4  Study Drug Exposure ................................................................................63  
8.7 Data Quality Assurance  ..........................................................................................63  
8.7.1  Data Management  .....................................................................................63  
9 Ethics  .............................................................................................................................. 64  
9.1 Independent Ethics Committee or Institutional Review Board  .............................64  
9.2 Ethical Conduct of the Study .................................................................................64  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 7 9.3 Patient Information and Consent ...........................................................................64  
10 Investigator’s Obligations ............................................................................................... 66  
10.1  Confidentiality  .......................................................................................................66  
10.2  Financial Disclosure and Obligations ....................................................................66  
10.3  Investigator Documentation ...................................................................................67  
10.4  Study Conduct ........................................................................................................67  
10.5  Adherence to Protocol............................................................................................67  
10.6  Adverse Events and Study Report Requirements ..................................................68  
10.7  Investigator’s Final Report ....................................................................................68  
10.8  Records Retention  ..................................................................................................68  
10.9  Publication s ............................................................................................................68  
11 Study Management ......................................................................................................... 69  
11.1  Monitoring .............................................................................................................69  
11.1.1  Monitoring of the Study ............................................................................69  
11.1.2  Inspection of Records ...............................................................................69  
11.2  Management of Protocol Amendments and Deviations .........................................69  
11.2.1  Modification of the Protocol .....................................................................69  
11.2.2  Protocol Deviations ..................................................................................70  
11.3  Study Termination  ..................................................................................................70  
11.4  Final Report ...........................................................................................................70  
12 Reference List  ................................................................................................................. 71  
13 Appendices ..................................................................................................................... 73  
13.1  Appendix: Schedule of Events ...............................................................................73  
13.1.1  Schedule of Study Procedures ..................................................................74  
13.1.2  Timing of ECG and Sample Collection for PK, ADA,  
 and PBMCs ..................................................................78  
13.2  Appendix: Response Assessment of Hodgkin and Non-Hodgkin Lymphoma 
(Lugano C lassification)  ..........................................................................................79  
13.3  Appendix: Global Response Score Grading Scales for Modified Severity -weighted Assessment Tool (mSWAT) for CTCL  ....................................83
 
13.3.1  Skin Scoring ..............................................................................................83  
13.3.1.1  Total Body Surface Area (TBSA) Involvement by Skin Disease  ................................................................................... 83
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019  Page 8 13.3.1.2  Severity Weighti ng Factor ..................................................... 83  
13.3.1.3  Calculating Skin Scores  ......................................................... 83  
13.3.1.4  Response Definitions ............................................................. 85  
13.3.2  Global Response Score  .............................................................................86  
13.4  Appendix: CTCAE Immune System Hypersensitivity Grades ..............................87  
13.5  Appendix: D ose Escalation Scheme Report  ..........................................................90  
13.5.1  Overview................................................................................................. 90 
13.5.2  Continual Reassessment Method  ..............................................................91  
13.5.3  Dose Escalation Rules  ..............................................................................92  
13.5.3.1  Starting Dose and Entry into the Study ................................. 92  
13.5.3.2  Assignment of Dose Level  ..................................................... 92  
13.5.4  Interim Monitoring  ...................................................................................93  
13.5.4.1  Safety Monitoring .................................................................. 93  
13.5.4.2  Success in Identifying the MTD ............................................ 93  
13.5.5  Operating Characteristics  ..........................................................................93  
13.5.5.1  All Doses Safe ....................................................................... 94  
13.5.5.2  MTD is the Highest Dose (0.30 mg/kg) ................................ 95  
13.5.5.3  MTD is a Middle Dose (0.15 mg/kg) .................................... 96  
13.5.5.4  MTD is a Middle Dose (0.10 mg/kg) .................................... 97  
13.5.5.5  MTD is a Low Dose (0.05 mg/kg) ......................................... 98  
13.5.5.6  MTD is a Low Dose (0.02 mg/kg) ......................................... 99  
13.5.5.7  No Doses Safe ...................................................................... 100  
13.6  Appendix: Clinical Case Definitions: Level 1 of Diagnostic Certainty  for 
Guillain -Barré Syndrome .....................................................................................101  
13.7  Appendix: Guillain–Barré Syndrome Disability S cale ........................................102  
List of Figures  
Figure 1.  Schematic Representation and Chemical Structure of ADCT-301 ......................... 21  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 9  
 
Protocol Synopsis  
Protocol N umber:  ADCT -301-001 
Title:  A Phase 1 Adaptive Dose -Escalation Study to Evaluate the Tolerability, 
Safety, Phar macokinetics, and Antitumor Activity of ADCT -301 in 
Patients with Relapsed or Refractory Hodgkin Lymphoma and 
Non-Hodgkin Lymphoma 
Sponsor:  ADC Therapeutics  SA 
Study Phase:  Phase 1 
Study S ites: Approximately 10 sites during dose-escalation (Part 1) and 13 sites during 
dose expansion (Part 2) 
Indication:  Refractory or relapsed lymphoma (per WHO Classification) defined as:  
• Non- Hodgkin lymphoma (NHL): Patients with histologically 
confirmed NHL (including stage ≥Ib cutaneous T- cell lymphoma 
[CTCL]) who have failed or are intolerant to any established therapy 
known to provide clinical benefit at current state of disease. 
• Hodgkin lymphoma : Patients with histologically confirmed classical 
Hodgkin lym phoma who have failed or are intolerant to any 
established therapy known to provide cl inical benefit at current state 
of disease.  
Rationale: Lymphoma cells have been reported to express cluster of differentiation 
(CD) 25 on their cell surface.  Expression of CD25 is positive (≥20% 
tumor cells) in approximately 58% to 78% of Hodgkin lymphoma, 42% to 50% of peripheral T-cell lymphoma, 54% of cutaneous T-cell lymphoma, 
and 40% of diffuse large B-cell lymphoma cases. 
ADCT -301 is an antibody drug conjugate (ADC), composed of the human 
monoclonal antibody, HuMax®- TAC, directed against CD25, and 
conjugated through a cleavable linker to SG3199, a 
pyrrolobenzodiazepine (PBD) dimer cytotoxin.  PBD dimers are highly 
efficient anticancer drugs that bind in the minor groove of DNA and form 
highly cytotoxic DNA interstrand cross-links .  After  binding and 
internalization, ADCT- 301 is transported to the lysosomes, where the 
protease sensitive linker is cleaved and free PBD dimers are released 
inside the target cell.  
The po tential for ADCT -301 in treating hematological malignancies that 
demonstrate CD25 over- expression has been shown by complete 
responses in mouse xenograft models following single, low -dose 
administration.  The efficacy of ADCT -301 in these models is due to 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 10 targeted delivery of the PBD cytotoxin SG3199.  
The safety of ADCT -301 has been as sessed in nonclinical testing.  
In mice, ADCT -301 is well tolerated at doses up to 9 mg/kg. 
A repeat -dose Good Laboratory Practice (GLP) toxicology study in 
cynomolgus monkeys i nvestigated doses ranging from 0.15 to 0.9 mg/kg.   
Toxicities included body weight loss, nephrotoxicity , and cutaneous 
adverse events (AEs).  The highest non-severe toxic dose was determined 
to be 0.15 mg/kg.   
Objectives:  Primary objectives : 
The primary objectives for Part 1 (dose escalation) and Part 2 (expansion) 
of the study are: 
• Evaluate the safety and tolerability and determine the maximum 
tolerated dose (MTD) of ADCT -301 in patients with 
relapsed/refractory lymphoma (Part 1). 
• Determine the recommend ed dose of ADCT-301 for Part 2. 
• Evaluate the safety and tolerability of ADCT -301 in Part 2 at the dose 
level recommended in Part 1. 
Secondary objectives : 
The secondary objectives for Part 1 and Part 2 of the study are: 
• Evaluate the activity of ADCT-301 measured by overall response rate, 
duration of response, progression-free survival, and overall survival. 
• Characterize the pharmacokinetic (PK) profile of HuMax-TAC 
(total antibody; drug-to -antibody ratio [DAR] ≥0), PBD-conjugated 
HuMax -TAC (DAR ≥1), and free warhead SG3199. 
• Evaluate anti -drug antibodies (ADA s) in blood before, during, and 
after treatment with ADCT-301. 
 
 
  
 
  
  
  
 
  
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 11 Patient  Selection: Inclusion Criteria:  
1. Male or female age 18 years or older. 
2. Refractory or relapsed lymphoma (per WHO Classification system) 
defined as:  
• Non- Hodgkin lymphoma (NHL): Patients with h istologically 
confirmed NHL (including stage ≥ Ib cutaneous T-cell lym phoma 
[CTCL]) who have failed or are intolerant to any established therapy 
known to provide clinical benefit at current state of disease.  There is 
no upper limit to the number of prior therapies. 
• Hodgkin lymphoma: Patients with h istologically confirmed cl assical 
Hodgkin lymphoma who have failed or are intolerant to brentuximab 
vedotin. Patients must have received a checkpoint inhibitor. There is 
no upper limit to the number of prior therapies.  
3. Pathologically confirmed relapsed or refractory lymphoma; a biopsy at any relapse is acceptable.  
4. Availability of formalin -fixed paraffin-embe dded (FFPE) tumor tissue 
block.  An FFPE block from a current biopsy is preferred; however, 
archival tissue taken at a ny prior relapse is acceptable.  If tissue block 
is not ava ilable, slides from a FFPE block may be acceptable for 
eligibility upon consultation with the Sponsor. 
5. Measurable  disease, defined by the 2014 Lugano Classification 
Criteria (including CTCL patients without evidence of skin disease) .  
CTCL patients with sk in disease and modified Severity -Weighted 
Assessment Tool (mSWAT) criteria >  0, or absolute S ézary count 
≥1000 cells/µL are eligible.  
6. Eastern Cooperative Oncology Group (ECOG ) performance status 0 to 
2. 
7. Absolute neutrophil count  (ANC)  ≥1500/µL. Criterion not applicable 
to adult T cell leukemia/lymphoma (ATLL) patients.  
8. Platelet count of ≥75000/µL. Criterion not applicable to ATLL 
patients.  
9. Hemoglobin ≥9.0 g/dL without transfusion within the 2 weeks prior to 
Day 1.  Criterion not applicable to ATLL patients. 
10. Serum/plasma  creatinine ≤1.5 mg/dL, or if the patient has a creatinine 
>1.5 mg/dL, a measured creatinine clearance must be > 80 mL/min as 
calculated by the Cockcroft and Gault equation. 
11. Serum/plasma  alkaline ph osphatase, alanine aminotransferase, and 
aspartate aminotransferase ≤2 times the upper limit of normal (ULN); 
≤5 times ULN if there is liver or bone involvement. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 12 12. Total serum /plasma  bilirubin ≤1.5 times ULN (patients with known 
Gilbert’s syndrome may have a total bilirubin up to ≤3 times ULN). 
13. Women of childbearing potential must have a negative blood 
beta-human chorionic gonadotropin (β-HCG) pregnancy test within 
7 days prior to Day 1. 
14. Women of childbearing potential* must agree to use a highly 
effective** method of contraception from the time of giving informed 
consent until at least 16 weeks after the last dose of ADCT -301.  
Men with female partners who are of childbearing potential must agree 
that they or their partners will use a highly effective method of 
contraception from the time of giving informed consent until at least 
16 weeks after the patient receives his last dose of ADCT-301.   
*Defined as: Sexually mature women who have not undergone 
bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or 
who have not been postmenopausal (i.e., who have not menstruated at 
all) for at least 1 year . 
**Defined as: H ormonal contraceptives  (oral , injectable, patch, 
intrauterine devices ), male partner sterilization, or total abstinence 
from heterosexual intercourse, when this is the preferred and usual 
lifestyle of the patient.  Note: The double-barrier method  
(e.g., synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), p
eriodic abstinence (such as calendar, 
symptothermal, post-ovulation), withdrawal (coitus interruptus ), 
lactational amenorrhea method, and spermicide -only are not 
acceptable as highly effective methods of contraception. 
Exclusion Criteria:  
1. Patients who have  an option for any treatment with proven clinical 
benefit for their lymphoid malignancy at current s tate of disease.  
2. Active graft-versus- host disease. 
3. Autologous or allogenic transplant within the 60 days prior to Cycle 1 
Day 1 
4. Evidence of myelodysplasia or myeloid leukemia by morphology, 
immunostains , flow cytometry, or cytogenetics on a bone marrow 
aspirate or biopsy. 
5. Known history of positive serum human ADA or known allergy to 
any component of ADCT-301. 
6. History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, 
systemic progressive sclerosis [scleroderma], systemic lupus 
erythematosus, Sjögren's syndrome, autoimmune vasculitis  
[e.g., Wegener's granulomatosis]). 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 13 7. History of  neuropathy considered of autoimmune origin  
(e.g., polyradiculopathy including Guillain -Barré syndrome (GBS) and 
myasthenia gravis); other central nervous system autoimmune disease 
(e.g., poliomyelitis, multiple sclerosis). 
8. History of recent infection (within 4 weeks of C1D1) considered to be 
caused by one of the pathogens listed in Section 7.3.4.5 : HSV1, HSV2, 
VZV, EBV, CMV, mea sles, Influenza A, Zika virus, Chikungunya 
virus, mycoplasma pneumonia, Campylobacter jejuni, or enterovirus 
D68. 
9. Known seropositive for human immunodeficiency virus (HIV), 
hepatitis B surface antigen (HbsAg), or antibody to hepatitis C virus 
(anti-HCV) wi th confirmatory testing and requiring anti -viral therapy.  
Note: testing is not mandatory to be eligible.  If patient is at risk for 
having undiagnosed HCV (e.g., history of injection drug use), 
HCV testing should be considered.  
10. History of Steven's Johnson's syndrome or toxic epidermal necrolysis 
syndrome. 
11. Pregnant or breastfeeding women. 
12. Significant medical comorbidities, including uncontrolled hypertension (diastolic blood pressure > 115 mm Hg), unstable angina, congestive 
heart failure (greater than N ew York Heart Association class  II), severe 
uncontrolled ventricular arrhythmias, or electrocardiographic evidence 
of acute ischemia, poorly controlled diabetes, severe chronic 
pulmonary disease, coronary angioplasty, or myocardial infarction 
within 6  months prior to screening, or uncontrolled atrial or ventricular 
cardiac arrhythmias.  
13. Use of any other experimental medication(s) within 14 days or 
5 half -lives , but in no case < 14 days prior to the start of study 
treatment  on Cycle 1, Day 1, except if approved by the Sponsor. 
14. Major surgery, radiotherapy, chemotherapy , or other anti-neoplastic 
therapy (including prednisone ≥ 40 mg/day or equivalent) within 
14 days or 5  half-lives (whichever is shorter) prior to Cycle 1, Day 1 
treatment , or shorter if approved by the Sponsor. 
15. Failure to recover (to Common Terminology Criteria for Adverse 
Events [CTCAE  Version 4.0] Grade 0 or Grade 1) from acute 
non-hematologic toxicity ( except all grades of alopecia or Grade 2 or 
lower neuropathy ), due to previous therapy, prior to Screening. 
16. Congenital long QT syndrom e or a corrected QTc interval ≥  450 ms at 
screening (unless secondary to pacemaker or bundle branch block).  
17. Active second primary malignancy other than non- melanoma skin 
cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or 
lobular ca rcinoma in situ of the breast, or other malignancy that 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 14 Sponsor  medical monitor and Investigator  agree and document should 
not be exclusionary.  
18. Any other significant medical illness, abnormality, or condition that 
would, in the Investigator ’s judgment, make the patient inappropriate 
for study participation or put the patient at risk. 
Study Design:  This is a P hase 1, first -in-human (FIH) , open-label study of ADCT -301 in 
patients with relapsed and refractory lymphoma  that will be conducted in 
2 parts.  
In Part 1 (dose-escalation), patients will receive a 1-hour intravenous  (IV) 
infusion of ADCT -301 on Day 1 every 3 weeks (21-day  cycle ) and the 
MTD will be determined . If ADCT -301 is well tolerated after the first 
cycle, the infusion duration may be shortened to 30 minutes for 
subsequent cycles for that patient, at the Investigator’s discretion. The 
starting dose of ADCT -301 will be  3 µg /kg (Dose  Level 1) and dose  
escalation will be conducted according to a continual reassessment 
method (CRM).    
The first patient to be treated at each new dose will be monitored for any 
AEs for 7 days before proceeding with dosing for a second patient. 
In Part 2 (expansion), patients will be assigned to receive the 
recommended dose (s) of ADCT -301 as determined by the 
Dose  Escalation Steering Committee ( DESC) during Part 1 of the study . 
The following dosing regimen(s) may be investigated based on safety and PK emerging information: 
• 45 µg/kg every 3 weeks  for 3 cycles followed by 30 µg/kg  every 
3 weeks for patients who have not pro gressed .   
• 45 µg/kg every 3 weeks  for 3 cycles followed by 20 µg/kg  every 
3 weeks for patients who have not progressed.   
• 45 µg/kg every 3 weeks  for 4 cycles followed by 30 µg/kg  every 
3 weeks for patients who have not progressed. 
• 45 µg/kg every 3 weeks  for 4 cycles followed by 20 µg/kg  every 
3 weeks for patients who have not progressed. 
The initial dose level for Part 1 will be 3 µg/kg ( Dose Level 1 ).  
The highest allowed dose will be 300 µg/kg.  The MTD will be the highest 
safe dose that has at least a 60 % probability that the dose-limiting -toxicity 
(DLT) rate is < 30%.  The  dose escalation design is described below. 
After discontinuation of treatment, patients without documented objective 
disease progression will be followed until progression of disease or 
initiation of new anticancer therapy for up to 12 months.  All patients will 
be followed for survival (by telephone contact or retrospective chart 
review) until a new anticancer therapy is initiated or for up to 12 months 
after treatment discontinuation. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 15 A DESC will be responsible for safety monitoring and overall supervision 
of the study .   
Estimated 
Duration of 
Patient 
Participation and 
Study Duration: For each patient, the study will include a screening period (up to 28 days), 
a treatment period (until withdrawal, see below ), and a follow -up period to 
assess disease progression and survival for up to 12 months after the last dose of study drug .  The total study duration will be dependent on overall 
patient tolerability to the study drug and response to  treatment . 
It is anticipated that the entire study (Parts 1 an
d 2) could last 
approximately 3 years from first patient treated to last patient completed.  
A patient may be withdrawn from the treatment  for any of the following 
reasons: 
• Objective disease pro gression 
• Clinical p rogression 
• AE 
• Withdrawal of consent 
• Major protocol deviation  
• Required treatment delay > 21 days (except in case of potential patient 
benefit, which must be approved by the Sponsor) 
• Non-compliance, including lost to follow-up 
• Pregnancy 
• Other (e.g., development of contraindications  with use of the study 
dug) 
• The Investigator determines if it is in the best interest of the patient to 
discontinue the patient’s participation in the study. 
• Discontinuation of the study by the Sponsor. 
• Death 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 16 Efficacy 
Assessments:  Response to ADCT -301 will be assessed through the evaluation of 
complete response (CR), partial response (PR), progressive disease (PD), and stable disease (SD) determined by the Investigator  
based on the 
Lugano Classification Criteria (2014) and Global Response Score Grading 
Scales for CTCL .  Disease assessments will  occur every other cycle for 
the first 2  evaluations (6 and 12 weeks), and every third cycle (every 9 
weeks) thereafter until progression or more frequently, if clinically 
indicated.  
Patients who discontinue treatment for any reason other than objective 
disease progression will continue to be followed with scans approximately 
every 12 weeks from the last tumor assessment until disease progression, 
or initiation of a new anticancer treatment .  If a patient discontinues 
treatment for a hematopoietic stem cell transplant, the frequency of 
imaging will be as per the transplant center standard of care .  
After  documentation of disease progression or start of a new anticancer 
treatme nt, patients will be contacted by telephone approximately every 
12 weeks for up to 12 months after the last dose of study drug to collect survival information. 
Pharmacokinetic  
and Anti- drug  
Antibody 
Assessments:  The concentration versus time profile of total antibody HuMax -TAC,  
PBD-conjugated HuMax- TAC and free warhead SG3199 in serum will be 
determined centrally in Cycles 1 and 2.  
In Cycles 1 and 2, sample  collection  for analysis of PK parameters will be 
performed before the start of the ADCT -301 infusion, end of the infusion, 
and at 1, 3, 6, 24, 48, 96, 168 (Day 8), and 336 hours (Day 15) after the end of the ADCT -301 infusion.  
In all subsequent cycles, PK blood 
samples will be collected before the start of the ADCT -301 infusion, 
at end of the infusion, at End of Treatment  (EOT) , and at 12 weeks 
following the last ADCT -301 infusion.  
Antidrug (ADCT -301) antibodies in serum will be measured centrally 
before the start of each ADCT -301 infusion,  at EOT , at 12 weeks 
following the last ADCT 301 infusion, and optionally in PK samples if 
needed. 
 
 
 
 
  
 
  
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 17 •  
 
  
 
 
 
  
 
Safety 
Assessments:  Safety will be assessed based on the evaluation of AEs, serious AEs 
(SAEs), treatment discontinuations due to AEs, DLTs , periodic 12-lead 
electrocardiogram (ECG) recordings, physical examinations, vital signs 
measurements, ECOG performance status, hematology, coagulation panel, 
biochemistry, pregnancy testing (for women of child- bearing potential) 
and urinalysis test results obtained at various time points  during the study .  
Adverse events will be graded according to CTCAE Version 4.0.  
Definitio n of DLT  A DLT is defined as any of the  following events , except those that are 
clearly due to underlying disease or extraneous causes: 
• A hematologic DLT is defined as (not applicable for ATLL patients): 
o Grade 3 or 4 febrile neutropenia or neutropenic infection.  
o Grade 4 neutropenia lasting > 7 days. 
o Grade 4 thrombocytopenia. 
o Grade 3 thrombocytopenia with clinically significant bleeding, or 
Grade 3 thrombocytopenia requiring a platelet transfusion. 
o Grade 4 anemia.  
• For ATLL patients, a hematologic DLT is defined as:  
o Any Grade 4 neutropenia lasting ≥ 42 days from the start of the 
cycle in the absence of evidence of residual leukemia.  
o Grade 3 or higher event of thrombocytopenia or a Grade 4 anemia, 
with a hypocellular bone marrow lasting for ≥ 42 days from the start 
of the cycle, in the absence of evidence of residual leukemia (i.e., 
with <5% malignant cells).  
• A non- hematologic DLT is defined as:  
o Grade 4 tumor lysis syndrome (Grade 3 TLS will not constitute DLT 
unless it leads to irreversible end-organ damage). 
o Grade 3 or higher (including nausea, vomiting, diarrhea, and 
electrolyte imbalances lasting ≥ 48 hours despite optimal therapy 
[excluding all grades of alopecia ]).  
o Grade 3 or higher hypersensitivity reaction (regardless of 
premedication). 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 18 o Skin ulceration ≥ Grade  2. 
o Peripheral sensory or motor neuropathy ≥ Grade 2. 
Note: The DLT observation period for dose escalation will be 1 cycle; 
however, the  adaptive dose -escalation algorithm will incorporate 
cumulative DLTs occurring through Cycle 3.  
Investigational 
Product, Dosage, 
and Mode of Administration: ADCT -301 is a sterile formulation containing PBD -conjugated 
HuMax -TAC (DAR ≥1), HuMax-TAC (DAR = 0), and SG3249.  It is 
provided pre -formulated in 10 mL glass vials containing approximately 
30 mg  ADCT -301 per vial (deliverable volume 5.4 mL at 6 mg/mL).  
Patients will receive ADCT-301 administered initially as a 1-hour IV 
infusion on Day  1 of each 3-week cycle.  If ADCT -301 is well tolerated 
after the first cycle, the infusion duration may be shortened to 30 minutes  
for subsequent cycles at the Investigator ’s discretion.  
Dose -Escalation 
Design : Dose levels from 3 to  300 μg/kg are possible. 
Dose escalation will be conducted according to a CRM .  Non- DLT 
toxicity events (i.e., Grade 2 or higher toxicities) will inform the 
probability of DLT at each dose level.  Dose escalation is also conducted 
according to a set of rules that govern entry into the study and assignment 
of dose level.  These rules allow that untried dose levels may be skipped .  
The trial is continuously monitored for safety and early stopping for 
successfully identifying the MTD. 
The final number of doses will be dependent on the emergent toxicity 
profile and will be decided by a DESC; PK and pharmacodynamic 
evaluations may also inform decision making.  
The DLT observation period for dose escalation will be  1 cycle; however, 
the adaptive dose -escalation algorith m will incorporate cumulative DLTs 
occurring through Cycle 3.  No intra -patient dose escalation will be 
allowed during the study .  However, once the recommended Part 2 dose (s) 
is determined, patients receiving lower or higher dose levels of 
ADCT -301 may be  offered continued treatment at the recommended dose. 
During Part 1, the DESC may expand enrollment at doses below the 
current dose level being evaluated as part of the dose escalation process .  
Additional patients may only be added at a lower dose level provided there is at least 1 patient with  documented stable disease.  Not more than 
10 patients in total can be treated at any dose level unless at least 3 of the 
10 
patients have documented partial response or better using the 
2014 Lugano Classification criteria2 or other appropriate measures of 
response. 
Sample Size: This is a Phase 1 study with a total sample size of approximately 
140 patients .  Part 1 may enroll approximately 80 patients and Part 2 will 
enrol l approximately 60 patients.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 19 List of Abbreviations  
Abbreviation  Definition  
ADA  
ADC  anti-drug antibody  
antibody drug conjugate  
AE adverse event  
AI accumulation index  
ANC  
ATLL  absolute neutrophil count  
adult T cell leukemia/lymphoma  
AUC 0-∞ area under the concentration -time curve from time zero to infinity  
AUC 0-last area under the concentration -time curve from time zero to the last 
quantifiable concentration  
AUC 0-τ area under the concentration -time curve from time zero to the end of the  
dosing interval  
β-HCG  beta human chorionic gonadotropin  
BSA  body surface area  
CBC  complete blood count  
CD cluster of differentiation  
CFR  Code of Federal Regulations  
CL clearance  
Cmax maximum concentration  
CMV  cytomegalovirus  
CR complete response  
CRM  continual reassessment method  
CRO  contract research organization  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTCL  cutaneous T -cell ly mphoma  
D5W  5% dextrose in water  
DAR  drug-to-antibody ratio  
DESC  Dose Escalation Steering Committee  
DLT  dose-limiting toxicity  
EBV  Epstein -Barr virus  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EOT  End of Treatment  
FDA  Food and Drug Administration  
FDG  18F-fluorodeoxyglucose  
FIH first-in-human  
FFPE  formalin -fixed paraffin -embedded  
GBS  Guillain -Barré syndrome  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
HCV  hepatitis C virus  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 20 Abbreviation  Definition  
HIV human immunodeficiency virus  
HbsAg  hepatitis B surface antigen (HbsAg)  
HSV1 / 2  Herpes Simplex Virus Type 1 / Type 2  
ICF informed consent form  
ICH International Co uncil for  Harmonisation  
IEC independent ethics committee  
IL-2R Interleukin  2 receptor  
INR International Normalized Ratio  
IRB institutional review board  
IV intravenous  
IVF intravenous fluid  
IVIg  intravenous immunoglobulin  
MRI  magnetic resonance imaging  
mSWAT  modified Severity -Weighted Assessment Tool  
MRT  mean residence time  
MTD  maximu m tolerated dose  
NHL  non-Hodgkin lymphoma  
PBD  pyrrolobenzodiazepine  
PBMC  peripheral blood mononuclear cell  
PD Progressive Disease  
PET positron emission tomography  
PK 
PLEX  pharmacokinetic  
plasma exchange  
PR partial response  
PT prothrombin time  
PTT Partial prothrombin time  
QWBA  Quantitative Whole Body Autoradiography  
SAE  serious adverse event  
SAP statistical analysis plan  
SD stable disease  
SPD sum of the product of the perpendicular diameters  
TAC  T-cell activation antigen  
TBSA  total body surfa ce area  
TEAE  treatment -emergent adverse event  
TLS tumor lysis syndrome  
λz terminal elimination phase rate constant  
Tmax time to maximum concentration  
T1/2 terminal half -life 
ULN  upper limit of normal  
Vss volume of distribution at steady -state 
VZ volume of distribution  
VZV  varicella zoster virus  
WBC  white blood cell  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 21 1 Introduction  
ADCT -301 is an antibody drug conjugate ( ADC ), composed of the human  monoclonal 
antibody , HuMax®- TAC,  directed  against human cluster of differentiation 25  (CD25 ), and 
conjugated through a cleavable linker to  SG3199, a pyrrolobenzodiazepine (PBD) dimer 
cytotoxin.  PBD dimers are highly  efficient anticancer drugs that bind in the minor groove of 
DNA and form highly cytotoxic DNA interstrand  cross- links.  The schematic repres entation 
of ADCT -301, and the different components that may be formed following the  administration 
of this ADC to humans, are presented in Figure 1. 
 
Figure 1.  Schematic Representation and Chemical Structure of ADCT -301  
Abbreviations: PABA, para -aminobenzoic aci d; PEG, polyethylene glycol.  
The make- up of ADCT -301 includes: 
• HuMax®-TAC: A human  monoclonal antibody of the IgG1, kappa isotype, specific for 
human CD25 . 
• SG3249:  A PBD  linker that c omprises the PBD dimer SG3199 and all linker components, 
including the m aleimide, 8 -polyethylene glycol , a protease -sensitive valine -alanine linker 
and a para-aminobenzoic acid self -immolative group. 
• SG3199:  A PBD dimer cytotoxin, which is a highly efficient anticancer drug due to its 
interstrand  cross -linking, a consequence of its specifically designed strong binding to the 
minor groove of DNA. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 22 CD25 or T -cell activation antigen (TAC) is the 55 kDa alpha chain of the interleukin-2 
receptor (IL -2R).  The IL- 2R is made up of three subuni ts:  α (CD25), β (CD122) and 
γ (CD132).  Lymphoma cells have been reported to express CD25 on their  cell surface.  
Expression of CD25 as detected by flow cytometry is positive (≥20% tumor cells) in 
approximately 58% to 78% of Hodgkin lymphoma, 42% to 50% of peripheral T -cell 
lymphoma , 54% of cutaneous T -cell lymphoma , and 40% of diffuse large B -cell lymphoma  
cases.12, 7, 10, 6  
ADCT -301 binds with picomolar affinity to human CD25.  After  binding and internalization, 
ADCT -301 is transported to the lysosomes, where the protease sensitive linker is cleaved and 
free PBD dimers are released  inside the target cell.  The released PBD dimers bind into the 
minor groove of DNA in a sequence -selective manner, and form highly cytotoxic DNA 
interstrand  cross -links .  The cross- links formed by PBD dimers are relatively non-distorting 
of the DNA structure, making them hidden to repair mechanisms, allowing for a longer effective period.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 23 2 Study Rationale and Justification for Dose Level Selection  
Study ADCT-301-001 is the first- in-human (FIH) clinical study with ADCT -301.  
The potential for ADCT -301 in treating hematological malignancies that demonstrate CD25  
over- expression has been shown by complete responses in mouse xenograft models 
following single , low- dose administration .  The efficacy of ADCT -301 in these models is due 
to targeted delivery of the PBD cytotoxin SG3199.  
The safety profiles of monoclonal antibodies directed against CD25 (IL -2Rα), such as 
Simulect® (basiliximab, Novartis Pharmaceuticals, NJ, USA) and Zenapax® 
(daclizumab,  Roche Pharmaceuticals , NJ, USA) have been well characterized .  Both products 
are indicated for prophylaxis of acute organ transplant rejection in patients re ceiving renal 
transplant .  The most frequently reported adverse events  (AEs)  identified in the prescribing 
information for both products are gastrointestinal disorders, including abdominal pain, 
constipation, diarrhea, nausea, and vomiting.8,11  
The safety of ADCT -301 has been assessed in nonclinical testing .  In mice, ADCT -301 is 
well tolerated at doses up to 9 mg/kg.  A repeat -dose Good Laboratory P ractice  (GLP)  
toxicology study in cynomolgus monkeys investigated doses ranging from 0.15 to 0.9 mg/kg.  
Systemic exposure to total ADCT -301 was consistent with the IV infusion route  and 
increased in a generally dose proportional manner .  No marked sex -related differences in 
exposure were noted .  No evidence of accumulation or changes in median time to maximum 
concentration (T max) and in mean terminal half -life (T 1/2), clearance (C L), and volume of 
distribution (V z) estimates were observed with increasing dose or on repeat dosing 
(where  total ADCT -301 was sufficiently quantifiable).  The average Day 1 ADCT -301 
maximum concentration (C max) (N=2 at each dose level) at 0.3  mg/kg, 0.6 mg /kg and 
0.9 mg/kg was 4,520 ng/mL, 12,450 ng/mL and 15,950 ng/mL , respectively .  The half -life 
(T1/2) of ADCT -301 ranged from 4.25 days to 7.54 days for doses 0.3 mg /kg to 0.9 mg/kg.  
Toxicities included body weight loss, nephrotoxicity and cutaneous AEs.  The highest  
non-severe toxic dose was determined to be 0. 15 mg/kg.  As per guidance from the Food and 
Drug Administration (FDA) , a starting dose of 10 µg/kg (one- sixth  of the highest non- severe 
toxic dose  based on body surface area  [BSA]) could be proposed for the FIH study.  
However,  based on anomalous exposure data observed on some  dosing days a t the 
0.15 mg/kg dose level (no explanation in the formulation or dosing records), a lower starting 
dose of 3 µg/kg ( Dose Level 1 ) was chosen for this study to offset a ny uncertainty associated 
with the 0.15 mg/kg dose level and to increase the margin of s afety . 
See the Investigator Brochure for ADCT -301 for additional information, including guidance 
for the Investigator.  
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 24 3 Study Objectives   
3.1 Primary Objectives 
The primary objectives for Part 1 (dose escalation) and Part 2 (expansion) of the study are: 
• Evalu ate the safety  and tolerability  and determine the maximum tolerated dose (MTD)  
of ADCT -301 in patients with relapsed/refractory lymphoma (Part 1).  
• Determine the  recommended dose of ADCT -301 for  Part 2 . 
• Evaluate the safety and tolerability of ADCT -301 in Pa rt 2 at the dose level 
recommended in Part 1. 
3.2 Secondary Objectives  
The secondary objectives for Part 1 and Part 2 of the study are: 
• Evaluate the activity of ADCT -301 measured by overall response rate, duration of 
response, progression-free survival, and overall survival. 
• Characterize the pharmacokinetic (PK) profile of HuMax- TAC (total antibody; 
drug- to-antibody ratio [ DAR ] ≥0), PBD- conjugated HuMax -TAC (DAR  ≥1), and free 
warhead SG3199. 
• Evaluate anti-drug antibodies  (ADAs ) in blood before, during, and after treatment  with 
ADCT -301. 
 
 
  
 
  
  
 
  
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 25 4 Investigational Plan  and Patient Selection  
4.1 Study De sign  
This is a Phase 1,  FIH, open- label, dose -escalation  (Part 1) and expansion (Part 2) study of 
ADCT -301 in patients with relapsed and refractory lymphoma.  The study will evaluate the 
safety and tolerability of ADCT -301 as monotherapy, as well as the p reliminary activity , PK, 
pharmacodynamics, and formation of ADAs of ADCT -301 in patients.  
For each patient, the study will include a screening period (up to 28 days), a treatment period 
(until progressive disease, intolerable toxicity, or withdrawal of co nsent) , and a follow -up 
period to assess disease progression and survival for up to 12 months after the last dose  of 
study drug.  The total study duration will be dependent on overall patient tolerability to the 
study drug and response to treatment.  It is anticipated that the entire study (Parts 1 and 2) 
could last approximately 3 years from first patient treated  to last patient completed.  
In Part 1, patients will receive ADCT -301 administered as a 1-hour IV infusion on Day 1 of 
each 3-week  (21-day) cycle.  If ADCT -301 is well tolerated after the first cycle, the infusion 
duration may be shortened to 30 minutes  for subsequent cycles at the Investigator ’s 
discretion .   
The first patient at each dose level will be monitored for any AEs for 7 days before proceeding with dosing for the second patient. 
The initial dose level for Part 1 will be 3 µg/kg ( Dose Level 1 ).  The highest allowed  dose 
will be 300 µg/kg.  The MTD will be the highest safe dose that has at least a 60% probability 
that the dose- limiting toxic ity (DLT ) rate is < 30%.   
After discontinuation of treatment, patients without documented objective disease 
progression will be followed until progression of disease or initiation of new  anticancer  
therapy for up to 12 months.  All patients will be follow ed for survival (by telephone contact 
or retrospective chart review) until a new anticancer therapy is initiated or for up to 12 months after treatment discontinuation.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 26 4.1.1 Dose Escalation and Determination of the Maximum Tolerated Dose 
(Part 1) 
Dose escalatio n will be conducted according to a continual reassessment method (CRM) 
(Section  13.5).  D ose levels from  3 to 300 μg/kg are possible. 
However, the final number of doses will be dependent on the emergent toxicity profile and 
will be decided by a Dose Escalation Steering Committee  (DE SC) ( Section 7.3.1.2).  
Pharmacokinetic and pharmacodynamic evaluations may also inform decision making. 
The DLT  observation period for dos e escalation will be 1 cycle; however, the adaptive 
dose- escalation algorithm will incorporate cumulative DLTs occurring through Cycle 3.  
No intra -patient dose  escalation will be allowed during the study.  However, once the 
recommended Part 2 dose (s) is determined, patients receiving lower or higher dose levels of 
ADCT -301 in Part 1  may be offered continued treatment at the recommended dose.  
During Part 1 , the DESC  may expand enrollment at doses below the current dose  level being 
evaluated as part of the dose escalation process.  Additional patients may only be added at a 
lower dose  level  provid ed there is at least 1 patient with documented stable disease.  
Not more than 10 patients in total can be treated at any dose level unless at least 3 of the 10 
patie nts have documented partial response or better using the 2014 Lugano Classification  
criteria2 or other appropriate measures of response ( Appendix 13.3).  
4.1.2 Dose Expansion (Part 2) 
In Part 2 (expansion), patients will be assigned to receive the recommended dose(s)  of 
ADCT -301, as determined by the DESC during Part 1 of the study.   
The following dos ing regimen(s)  may be investigated based on safety and PK emerging 
information: 
• 45 µg/kg every 3 weeks  for 3 cycles followed by 30 µg/kg every 3 weeks for patients who 
have not progressed.   
• 45 µg/kg every 3 weeks  for 3 cycles followed by 20 µg/kg every 3 weeks for patients who 
have not progressed.   
• 45 µg/kg every 3 weeks  for 4 cycles followed by 30 µg/kg every 3 weeks for patients who 
have not progressed. 
• 45 µg/kg every 3 weeks  for 4 cycles followed by 20 µg/kg every 3 weeks for patients who 
have not progressed. 
The patient population (e.g., disease subtypes) to be enrolled in Part 2 (expansion) may be 
refined based on results and observations from Part 1. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 27 4.2 Selection of Study Population 
It is estimated that a pproximately  140 patients (a pproximately 80 patients in Part  1 and 
approximately 60 patients in Part 2) will be enrolled at  approximately 10 sites in Part 1 and 
13 sites in Part 2 of the study .  Patients will be assigned to a study treatment only if they meet 
all of the inclusion criteria and none of the exclusion criteria.  
4.2.1 Inclusion Criteria  
1. Male or female age 18 years or ol der. 
2. Refractory or relapsed lymphoma (per WHO Classification system) defined as:  
• Non-Hodgkin lymphoma (NHL): Patients with h istologically confirmed NHL 
(including stage ≥ Ib cutaneous T- cell lymphoma [CTCL]) who have failed or are 
intolerant to  any established therapy known to provide clinical benefit at current state 
of disease.  There is no upper limit to the number of prior therapies. 
• Hodgkin lymphoma: Patients with h istologically confirmed classical Hodgkin 
lymphoma who have failed or are intolerant to  brentuximab vedotin. Patient s must 
have received a checkpoint inhibitor . There is no upper limit to the number of prior 
therapies.  
3. Pathologically confirmed relapsed or refractory lymphoma; a biopsy at any relapse is 
acceptable.  
4. Availability of formalin -fixed paraffin- embedded (FFPE) tumor tissue block . 
An FFPE block from a current biopsy is preferred; however , archival tissue taken at any 
prior relapse is acceptable.  If tissue block is not available, slides from a FFPE block may 
be acceptable for eligibil ity upon consultation with the Sponsor. 
5. Measurable disease, defined by the 2014 Lugano Classification Criteria (including CTCL 
patients without evidence of skin disease) ( Appendix 13.2) .  CTCL patients with skin  
disease and modified Severity- Weighted Assessment Tool  (mSWAT) criteria >0, or  
absolute Sézary count ≥ 1000 cells/µL are eligible  (Appendix 13.3). 
6. ECOG performance status 0 to  2. 
7. Absolute neutrophil  count (ANC)  ≥1500/µL. Criterion not applicable to adult T cell 
leukemia/lymphoma (ATLL) patients.   
8. Platelet count of ≥75000/µL. Criterion not applicable to ATLL patients.  
9. Hemoglobin ≥9.0 g/dL without transfusion within the 2 weeks prior to Day 1. Criterion  not applic able to ATLL patients.  
10. Serum /plasma  creatinine  ≤1.5 mg/dL, or if the patient has a creatinine > 1.5 mg/dL, 
a measured creatinine clearance must be > 80 mL/min as calculated by the Cockcroft and 
Gault equation.4 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 28 11. Serum /plasma alkaline phosphatase, alanine aminotransferase, and aspartate 
aminotransferase ≤2 times the upper limit of normal (ULN); ≤  5 times ULN if there is 
liver or bone involvement. 
12. Total serum /plasma bilirubin ≤ 1.5 times ULN (patients with known Gilbert’s syndrome 
may have a total bilirubin up to ≤3 times ULN). 
13. Women of childbearing potential must have a negative blood beta -human chorionic 
gonadotropin (β- HCG) pregnancy test within 7 days prior to Day 1 . 
14. Women of childbearing potential* must agree to use a highly effective** method of 
contraception from the time of giving informed consent until at least 16 weeks after the last dose of ADCT -301.  Men with female partners who are of childbearing potential must 
agree that they or their partners will use a  highly effective method of contraception from 
the time of giving informed consent until at least 16 weeks after the patient receives his last dose of ADCT -301.   
*Defined as: Sexually mature women who have not undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or who have not been postmenopausal (i.e., 
who have not menstruated at all) for at least 1 year. 
**Defined as: Hormonal contraceptives (oral, injectable, patch, intrauterine devices), 
male partner sterilization, or total abs tinence from heterosexual intercourse, when this is 
the preferred and usual lifestyle of the patient .  Note:  The d ouble- barrier method (e.g., 
synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, post -ovulation), withdrawal 
(coitus interruptus), lactational amenorrhea method, and spermicide -only are not 
acceptable as highly effective methods of contraception. 
4.2.2 Exclusion Criteria  
1. Patients who have an option for any treatment with proven clinical benefit for their 
lymphoid malignancy at current state of disease.  
2. Active graft -versus- host disease.  
3. Autologous or allogenic transplant within the 60 days prior to Cycle 1 Day 1 
4. Evidence of myelodysplasia or myeloid leukemia by morphology, immunostains , flow 
cytometry, or cytogenetics on a bone marrow aspirate or biopsy. 
5. Known history of positive serum human ADA  or known allergy to any component of 
ADCT -301. 
6. History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemi c 
progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjögren's syndrome, autoimmune vasculitis [e.g., Wegener's granulomatosis]);  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 29 7. History of neuropathy considered of autoimmune origin (e.g., polyradiculopathy 
including Guillain -Barré syndrome and myasthenia gravis); other central nervous system 
autoimmune disease (e.g., poliomyelitis, multiple sclerosis).  
8. History of recent infection (within 4 weeks of C1D1) considered to be caused by one of 
the pathogens listed in Section 7.3.4.5: HSV1, HSV2, VZV , EBV , CMV , measles, 
Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter 
jejuni, or enterovirus D68. 
9. Known seropositive for human immunodeficiency virus (HIV), hepatitis B surfa ce 
antigen (HbsAg), or antibody to hepatitis C virus (anti -HCV) with confirmatory testing 
and requiring anti -viral therapy .  Note:  testing is not mandatory to be eligible .   
If patient is at risk for having undiagnosed HCV (e.g., history of injection drug use), 
HCV testing should be considered.  
10. History of Steven's Johnson's syndrome or  toxic epidermal necrolysis syndrome. 
11. Pregnant or breastfeeding women.  
12. Significant medical  comorbidities, including uncontrolled hypertension (diastolic blood 
pressure > 115 mm Hg ), unstable angina, co ngestive heart failure (greater  than New York 
Heart Association class II), severe uncontrolled ventricular arrhythmias, or 
electrocardiographic evidence of acute ischemia, poorly controlled diabetes, severe chronic pulmonary dise ase, coronary angioplasty , or myocardial infarction within 
6 months prior to screening, or uncontrolled atrial or ventricular cardiac arrhythmias.  
13. Use of any other experimental medication (s) within 14 days or 5 half -lives, but in no case 
< 14 days prior to  the start of study treatment on Cycle 1, Day 1, except if approved by 
the Sponsor. 
14. Major surgery, radiotherapy , chemotherapy, or other anti -neoplastic therapy 
(including prednisone ≥ 40 mg/day or equivalent) within 14 days or 5 half -lives 
(whichever is sh orter) prior to  Cycle 1, Day 1 treatment, except if approved by the 
Sponsor. 
15. Failure to recover (to Common Terminology Criteria for Adverse Events [CTCAE  
Version 4.0] Grade 0 or Grade 1) from acute non-hematologic toxicity 
(except  all grades of alopecia or Grade 2 or lower neuropathy), due to previous therapy, 
prior to Screening . 
16. Congenital long QT syndrome or a corrected QTc interval ≥ 450 ms at screening  
(unless secondary to pacemaker or bundle branch block). 
17. Active second primary malignancy other than non- melanoma skin cancers, nonmetastatic 
prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of  the breast , or 
other malignancy that Sponsor M edical Monitor and Investigator agree , and document 
should not be exclu sionary .  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 30 18. Any other significant medical illness, abnormality, or condition that would, in the 
Investigator ’s judgment, make the patient inappropriate for study participation or put the 
patient at risk . 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 31 5 Study Procedures  
5.1 Procedures by Study Day 
The following procedures will be performed during the study. 
5.1.1 Screening Period (Day –28 to –1) 
The following procedures will be performed within 28 days prior to Day 1 :  
• Signed and dated I nstitutional Review Board (IRB) /Independent E thics Committee 
(IEC) approved informed consent  form (ICF) obtained prior to performing any study 
evaluations .  Results (e.g., from laboratory tests or radiographic evaluatio ns, etc.) 
obtained prior to the date of informed consent but within the allowed timeframe for 
screening may be used for determination of patient eligibility only if obtained as part of 
the patient’s standard of care. 
• Demography. 
• Medical history (to include  a complete history of all surgeries and significant diagnoses  
and all cancer treatment [including surgery, radiation therapy, chemotherapy, etc .]) and 
assessment of cardiac risk factors (e.g., history of angina pectoris, coronary artery disease or cerebro vascular accident, transient ischemic attack, cardiac failure with 
known ejection fraction < 40%, or cardiac arrhythmia requiring medical therapy). 
• Pregnancy test (serum or urine, women of childbearing potential only). 
•  
 
   
• Physical examination, including neurological examination and including whole body 
skin assessment .  Whole body skin assessment does not have to be performed by a 
dermatologist ; however, any unexplained lesion will be referred  to a dermatologist for 
further evaluation  and skin biopsy , if clinically warranted . The examination must 
include a determination if the patient has had any infection.  At the discretion of the investigator, evaluation of any reported infection must be conducted to rule out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the exclusion criteria.  
o Neurological assessment (as part of the physical examination) including strength, 
sensation , and deep- tendon reflexes throughout; examination does not need to be 
conducted by neurologist unless there are abnormal findings not explained by previous medical history (e.g., a patient with left sided weakness known to be a 
result of a previous CV A would not need to see a neurologist as part of this study)  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 32 and that could be linked to or may be an early indicator of polyradiculopathy /GBS, 
such as ascending (bilateral) sensory loss or motor weakness. 
• Vital sign measurements .  
• Height. 
• Weight. 
• Eastern Cooperative Oncology Group (ECOG) performance status. 
• Disease assessment s:  Assessed  using positron emission tomography - computed 
tomography (PET -CT) and diagnostic CT of the  neck/chest/abdomen/pelvis and other 
areas of known disease or newly suspected disease with a clinical examination for 
lymphoma .  Contrast should be used unless contraindicated. Magnetic resonance 
imaging (MRI) is permitted if diagnostic CT is contraindicated .  The same assess ments 
methods used at Screening which identify sites of disease should be used uniformly for 
all subsequent assessments. 
Note:  PET-CT is only required at screening for 18F-fluorodeoxyglucose ( FDG) avid, 
nodal lymphomas (defined as per the Lugano Classifica tion criteria as essentially all 
eligible histologies except small lymphocytic lymphoma, lymphoplasmacytic 
lymphoma/Waldenstrom’s macroglobulinemia, mycosis fungoides, and marginal zone NHLs, unless there is a suspicion of aggressive transformation) . If PET-CT examination 
is negative at Screening, subsequent PET -CT is not required.  If PET -CT is positive, 
subsequent diagnostic CT and MRI are not needed , unless clinically  indicated . 
• Hematology. 
• Coagulation panel. 
• Biochemistry . 
• Urinalysis . 
• 12-lead electrocardiogram (ECG). 
• AEs. 
• Concomitant medication use  (including prescription or over -the-counter medication, 
herbal or naturopathic products ) within the 14 days prior to Day 1. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 33 5.1.2 Day 1 (± 3 days) of Each Cycle  
Day 1 of each cycle occurs on infusion day. The following procedures will be performed 
prior to ADCT -301 infusion unless otherwise specified : 
• Serum or urine pregnancy test (women of childbearing potential , Cycle 1 only) is not 
required if  screening  pregnancy test was performed using serum  and was done <  7 days 
before dosing with negative result.  
• Physical examination, including neurological examination and including whole body 
skin assessment , unless a physical examination  was performed within 3 days prior to 
Day 1 . The examination must include a determination if the patient has had any 
infection.  At the discretion of the investigator, evaluation of any reported infection must be conducted to rule out infection with a microorganism that may be associated 
with autoimmune or neurological disease(s) as specified i n the exclusion criteria.  
• On Day 1 of Cycle 1, vital signs (arterial blood pressure, heart rate, respiratory rate , 
temperature) are measured before the start of the infusion , every 30 minutes during the 
infusion, and at the end of infusion.  If no clinical ly significant changes occur during 
the first infusion, measurements are required prior to infusion start, hourly during infusion, and end of infusion for all subsequent infusions.  For Cycles 1 and 2, patients will be monitored for 4 hours post -infusion with vital signs being measured 1 hour after 
the end of infusion and at discharge. 
Note:   Timing of measurements is ± approximately 5 minutes. 
• Weight, unless an assessment was performed within 3 days prior to Day 1. 
• ECOG performance status, unless an assessment was performed within 3 days prior to 
Day 1.   
• Disease assessments:  
o To be performed within 6 days prior to Day 1 of Cycles 3 and 5 and thereafter 
every third cycle (i .e., Cycles 8, 11, 14, etc.), until disease progression or more 
frequently, if clinica lly indicated.  
o The same methods used at Screening which identify sites of disease should be 
used uniformly for all subsequent assessments. 
Note:   The results of the disease assessment are to be available to the Investigator 
prior to administration of stud y drug. 
Note:  if PET -CT examination is negative at Screening, subsequent PET -CT is not 
required.  For CTCL patients with disease limited to the skin, disease assessments 
after screening will be  performed using mSWAT; radiological imaging after 
screening fo r CTCL patients  with disease limited to the skin  is not required unless 
clinically indicated.   
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 34 • Hematology, coagulation panel, and biochemistry parameters will be measured prior to 
dosing unless the last sample was collected:  
o <24 hours before the start of ADCT 301 infusion on Day 1 of Cycle 1, or 
o <72 hours before the start of ADCT -301 infusion on Day 1 of Cycle 2 and 
subsequent cycles.  
• Urinalysis and sample collection for additional renal function studies will be done prior 
to dosing unless the last sample was collected:  
o <24 hours before the start of ADCT 301 infusion on Day 1 of Cycle 1, or 
o <72 hours before the start of ADCT -301 infusion on Day 1 of Cycle 2 and 
subsequent cycles.  
• 12-lead ECG (see Section 7.3.5 for timing of serial ECG measurements ).  
• Sample collection for central laboratory assessment of  PK, , ADA , 
(for additional sample collections  following dosing, see Appendix 13.1.2).  
• Sample collection and shipment for PBMC subset analysis  (Cycles 1 and 2, 
for additional sample collections  following dosing see Appendix 13.1.2; only in  
Study Part  2).  
• Sample collection  for , Cycles 1 and 2.  
• Sample collection  for , Cycles 1 and 3. 
• AEs.  
• Concomitant medication use.  
• Premedication administration , if applicable ( Section  6.2).  
• ADCT -301 administration. 
5.1.3 Day 8 (± 1 day) of Each Cycle 
• Physical examination, including neurological examination and including whole body 
skin assessment .  Whole body skin assessment does not have to be performed by a 
dermatologist; however, any unexplained lesion will be referred to a dermatologist for furthe r evaluation and skin biopsy, if clinically warranted (Cycles 1 and 2).  
The examination must include a determination if the patient has had any infection.  
At the discretion of the investigator, evaluation of any reported infection must be 
conducted to rule out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the exclusion criteria.  
• Weight  
• Vital sign s.  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 35 • Hematology.  
• Biochemistry .  
• Urinalysis . 
• Additional renal function studies. 
• PK blood sample collection  (Cycles 1 and 2).  
• Sample collection and shipment for PBMC subset analysis (Cycles 1 and 2, for 
additional sample collections following dosing see Appendix 13.1.2; only in 
Study Part  2).  
• AEs.  
• Concom itant medication use .  
5.1.4 Day 15 (± 1 day)  
• Physical examination, including neurological examination and including whole body 
skin assessment .  Whole body skin assessment does not have to be performed by a 
dermatologist; however, any unexplained lesion will be referred to a dermatologist for 
further evaluation and skin biopsy, if clinically warranted (Cycles 1 and 2).  The examination must include a determination if the patient has had any infection.  
At the discretion of the investigator, evaluation of any reported infection must be 
conducted to rule out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the exclusion criteria.  
• Weight  
• Vital signs (Cycles 1 and 2). 
• Hematology.  
• Biochemistry .  
• Urinalysis . 
• Additional renal function studies. 
• Sample collection for analysis of PK. 
• Sample collection and shipment for PBMC subset analysis (Cycles 1 and 2 , for 
additional sample collections following dosing see Appendix 13.1.2; only in 
Study Part  2).  
• AEs.  
• Concomitant medication use.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 36 5.1.5 End of Treatment Visit   
The following procedures will be performed as soon as possible after decision to discontinue 
the study drug and prior to initiation of anticancer treatment: 
• Serum or urine pregnancy test. 
• Physical examination, including neurological examination and including whole body 
skin assessment .  Whole body skin assessment does not have to be performed  by a 
dermatologist ; however, any unexplained lesion will be referred to a dermatologist for 
further evaluation  and skin biopsy , if clinically warranted .  The examination must 
include a determination if the patient has had any infection.  At the discretion of the 
investigator, evaluation of any reported infection must be conducted to rule out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the exclusion criteria.  
• Vital sign measurements .  
• ECOG performance status.  
• Weight 
• Disease assessment s: 
o Patients who already have documented objective disease progression do not need to 
have assessments repeated . 
o Patients who do not already have documented objective disease progression will have 
assessments performed at the end of treatment visit if the  most recent disease 
assessment was > 9 weeks prior to the end of t reatment visit.  
• Hematology.  
• Coagulation panel. 
• Biochemistry .  
• Urinalysis . 
• Additional renal function studies. 
• 12-lead ECG.  
• Sample collection for central laboratory assessment of PK, , ADA, and 
 
• Sample collection and shipment for PBMC subset analysis (only in Study Part 2).  
• AE collection (collected until 84 days [12 weeks] after last dose of study drug). 
• Concomitant medication use.  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 37 5.1.6 Long- term Follow -up 
Patients who discontinue treatment for any r eason  other than objective disease progression  
will continue to be followed with scans approximately every 12 weeks from the last tumor 
assessment until disease progression , or initiation  of new anticancer treatment .  If a patient 
discontinues treatment for a hematopoietic stem cell transplant, the frequency of imaging will 
be as per the transplant center standard of care.  
After documentation of disease progression  or start of new anticancer treatment , patients will 
be contacted  by telephone approximately e very 12 weeks for up to 12 months after the last 
dose of study drug to collect survival information. 
Blood Sample Collection and Adverse Event Monitoring During Long -Term Follow -up 
For all patients, PK and ADA blood sample collection will be performed 1 2 weeks 
(± 1 week) following the last dose of ADCT -301, unless a new anticancer treatment has been 
initiated . 
Patients who test positive for ADAs may be requested to supply additional ADA samples.  
For all patients, collection of AEs and SAEs will continue for  12 weeks after the last dose of 
study drug or initiation of new  anticancer treatment (see Section 7.3.2.2). 
5.2 Withdrawal of Patients  from the Study  
The duration of the study participation for each patient is defi ned as the time from the date of 
signed written informed consent  through the completion of the follow -up period or 
withdrawal of consent . 
5.2.1 Reasons for Withdrawal /Discontinuation  
Patients may withdraw from treatment  at any time and for any reason without pre judice to 
their future medical care by the Investigator or others at the study site.  A patient may be 
withdrawn from treatment for any of the following reasons: 
• Objective disease progression . 
• Clinical progression . 
• AE. 
• Withdrawal of consent. 
• Major  protocol  deviation. 
• Required t reatment delay > 21 days (e xcept in case of potential patient benefit, 
which  must  be approved by the Sponsor). 
• Non-compliance, including lost to follow-up. 
• Pregnancy 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 38 • Other  (e.g., development of contraindications with  use of the study drug). 
• The Investigator de termine s if it is in the best interest of the patient to discontinue the 
patient ’s participation in the study. 
• Discontinuation of the study by the Sponsor. 
• Death . 
 
5.2.2 Handling of Withdrawals 
Upon occurrence of a serious or intolerable AE, the Investigator will confer with the Sponsor .  
If a patient discontinues because of an AE, then the event will be followed until it is resolved.  
When a patient withdraws from the study, the reason(s) for withdrawal shall be recorded by 
the Investigator on the relevant page of the electronic case report form ( eCRF) .  
Whenever possible, all patient s who discontinue study treatment or withdraw from the stud y 
prematurely will undergo all e nd of t reatment  assessments.  Patients  who fail to return for 
final assessments will be contacted by the site.  Following a minimum of two documented 
unsuccessful telephone calls, a registered letter will be sent to the patient  in a final attempt to 
ensure protocol compliance. 
5.2.3 Patient Replacements  
Patients in Part 1 who  discontinue treatment for any reason without a DLT AE before 
completion of the first treatment cycle will be replaced .  No other patients will be replaced. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 39 6 Study Treatments 
6.1 Method of Assigning Patients to Treatment Groups  
This is an open -label study that will be conducted in 2 parts .  In both parts, ADCT -301 will 
be administered  on Day 1 of each cycle.  The duration of each cycle will be 21 days 
(3 weeks) .  
In Part 1, dose escalation will begin with the 3 µg/kg dose  starting dose  (Dose Level 1 ).  
The maximum dose will be 300 µg/kg.  Patients will be assigned to the appropriate dose level 
according to the CRM design ( Section  13.5) and judgment of the DESC . 
In expansion ( Part 2), all patients will be assigned to th e dose level of  ADCT -301 as 
identified in Part 1  by the DESC .  
6.2 Prophylactic Treatments  for Hypersensitivity  
If Grade 2 or higher infusion- related hypersensitivity reactions are observed in a patient  at 
any time during the study, this patient must receive p rophylactic treatment with all 
subsequent dosing, as described below or as per the institution’s standard of care, to reduce 
the risk of hypersensitivity reactions: 
• Patient will be instructed to take 20  mg of dexamethasone orally at 12 hours and 
6 hours be fore the start of ADCT -301 infusion on Day 1 of each cycle.  When necessary, 
12 and 6 hours before the first infusion may be  defined as  “immediately  before 
sleeping ” and “immediately after waking up .” 
• Patient will be given 50  mg of diphenhydramine hydrochl oride intravenously 
30 minutes before the start of the ADCT-301 infusion on Day 1 of each cycle.  
• Patient will be given 50  mg of ranitidine intravenously 30 minutes before the start of 
ADCT -301 infusion on Day 1 of each cycle.  
• For 2 days after administratio n of ADCT -301, dexamethasone 4  mg (twice per day) will 
be taken orally  by the  patient.  
Other  doses and other  medications for prophylaxis and treatment of hypersensitivity or 
infusion reactions may be administered according to standard treatment center prot ocols.  
Medications for the treatment of severe hypersensitivity reactions including anaphylaxis  
should be available for immediate use.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 40 If a Grade  1 or Grade  2 hypersensitivity occurs in a patient, the following medications should 
be administered  for 48 hours after  ADCT -301 infusion: 
• Ranitidine 150 mg orally given 2 times  per day 
• Diphenhydramine hydrochloride 50 mg orally given 3 times per day 
If a Grade  3 or higher hypersensitivity occurs, the patient should be discontinued from the 
study and must be treat ed immediately  with hydrocortisone 20 mg administered 
intravenously and/or other  appropriate medications .  In case of life- threatening symptoms 
(e.g., arrhythmia, hypotension, respiratory distress, seizures, shock, stridor, unconsciousness, 
wheezing), epinephrine 0.2 to 0.5 mL of 1:1000 dilution should be administered subcutaneously or intramuscularly , repeating every 5 minutes to a total dose of 1 mg.  
In these cases , patients must be carefully  observed after the treatment .  Additional therapy 
per institution standard of care should also be followed. 
6.3 Treatments Administered  
Part 1 of the study will investigate ADCT -301 administration  every  3 weeks.  In Part 2, 
all patients will be assigned to the dose level  identified in Part 1 by the DESC .  ADCT -301 
will b e administered on Day 1 of each cycle as a 1-hour IV infusion.  If ADCT -301 is well 
tolerated after the first cycle, the infusion duration may be shortened as a 30 minutes  IV 
infusion for subsequent cycles,  at the Investigator’s discretion . 
Variation in in fusion times due to minor differences in IV bag overfill/ underfill and the 
institution’s procedure for flushing chemotherapy lines will not result in protocol deviations.   
Prophylactic antiemetic medications , electrolyte supplementation, and other standar d 
supportive care measures may be administered according to standard treatment center  
protocols.  
Although the study patient population has a low risk for development of tumor lysis 
syndrome (TLS) compared to patients with acute disease,1 patients should be observed for 
development of TLS and treated according to standard treatment center protocols . 
Because of non- clinical observations related to nephropathy and adrenal gland changes, 
adequate patient hydration (e.g., 8  to 10 glasses of water or equivalent per day) is 
recommended for patients receiving ADCT -301. 
Available pre- clinical data on ADCT -301 does not suggest a photosensitivity concern, based 
on the lack of any signals in the rat and monkey toxicology studies with ADCT -301 and the 
non-clinical experience with SG3199, including a QWBA study indicating no specific 
accumulation to melanin containing tissues, skin or eyes.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 41 However, skin rash has been reported in the ADCT -301 program, as well as with another 
investigational agent containing the same pyrollobenzodiazepine warhead.3  The rash has 
been limited to areas at risk for sun exposure; it is therefore recommended that precautions 
are taken to avoid prolonged exposure of skin to direct sunlight. 
6.4 Dose Delays and Modifications 
The Investigator  may suspend ADCT -301 dosing for up to 21 days for any patient who 
experiences a protocol-defined DLT during any treatment cycle.   
At the discretion of the Investigator , the d ose may also be delayed for up to 21 days for any 
other toxicity  of any grade.   
Resumption of dosing with ADCT -301 after any suspension, even when longer than 21 days , 
is at the discretion of the Investigator, in consultation with the Sponsor, based on as sessment 
of the patient’s clinical condition and whether or not the patient is deriving potential clinical 
benefit from treatment with ADCT -301. Following recovery to Grade  1 or baseline , 
treatment may resume at the Investigator’s discretion.   
Patients wh o resume treatment following a dose delay  may, at the discretion of the 
Investigator, have their dose reduced by 1 dose level  in either part of the study.  If toxicity 
reoccurs at a severity that would mandate a dose delay, then the dose may be further reduced 1 dose level.  If toxicity reoccurs at such level, then the patient is to be discontinued from treatment. Dose re -escalation is allowed at the investigator’s discretion, at maximum to the 
dose level the patient was initially assigned to.  
Patients experiencing certain types of infection during the course of participation in this clinical study also must delay further dosing, as stipulated in Section 7.3.4.5. 
Patients experiencing any autoimmune toxicities (e. g. endocrinopathies) ≥ Grade 1 need to be 
followed at least weekly to quickly detect deterioration and modify dosing as per DLT 
criteria (can be done by telephone unless symptoms worsen). 
Patients experiencing the following significant toxicities will be i mmediately and 
permanently withdrawn from treatment with ADCT -301: 
• Any patient who experience s a Grade  3 or higher hypersensitivity reaction, regardless 
of premedication,  during any cycle of treatment  per CTCAE definitions 
(Appendix 13.4).  
• Any patient who experience s a recurrent Grade  3 or 4 toxicity excluding hematological 
toxicity . 
• Any patient who requires a dosing delay > 21 consecutive days from the planned Day  1 
dosing at any time during treatment (e xcept in case of  potential patient benefit, which 
must be approved by the Sponsor). 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 42 Neurological toxicities: dose delay/permanent discontinuation  
Patients experiencing any new neurological toxicities  ≥ Grade 1 , not explained by previous 
medical history , that could be linked to or may be an early  indicator of 
polyradiculopathy /GBS , such as ascending (bilateral) sensory loss or motor weakness, need to 
be immediately evaluated by a neurologist  and dosing of ADCT -301 needs to be delayed  
until polyradiculopathy/GBS is ruled out. Should further clinical, radiologic , or laboratory 
evidence support the diagnosis of polyr adiculopathy/GBS with the level 1 of diagnostic 
certainty ( Appendix  13.6) , treatment with ADCT -301 must be stopped and patient must be 
permanently discontinued. 
Patients  with Grade ≥ 3 neurologic toxicities defined as peripheral sensory and peripheral 
motor neuropathies must be permanently discontinued. Other new neurological findings  not explained by previous medical history increase of 
≥ 1 grade over baseline  will result in dose delay ; dosing may be resumed after resolution to 
baseline, at the investigator ’s discretion. The patient must be carefully monitored at least  
weekly  until such resolution  (can be done by telephone unless symptoms worsen). 
6.5 Study S topping Rules 
The study will be paused if any of the following circumstances occur: 
• ≥ 30% of patients experience a specific Grade 4 or higher non-hematologic 
treatment- emergent AE.  
• if any patient in Part 1 or Part 2 experiences a CTCAE Grade 5 AE, or 2 non-hematologic 
CTCAE Grade 4 AEs that are not attributable to the underlying disease, and for which relationship to ADCT -301 cannot be ruled out, within 30 days of their  last dose of 
ADCT -301. 
Furthermore, the Sponsor will notify regulatory agencies within 48 hours of being made aware of any new confirmed cases of GBS/polyradiculopathy to discuss, if appropriate, and 
determine whether or not the benefit -risk ratio has changed and dosing of additional patients 
and/or dosing of ongoing patients must be stopped. IRBs/IECs will be informed about the outcome of the assessment as appropriate.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 43 6.6 Identity of Investigational Product  
ADC Therapeutics will provide and distribute adequa te supplies of ADCT -301 to the study 
sites.  The following drug supplies will be used in the study:  
Product  Supplied As:  
ADCT -301 10 mL glass vial at a deliverable volume of 5.4 mL at 6 mg /mL 
(equivalent to 30 mg ADCT -301) 
 
6.6.1 ADCT -301 Drug Product  
ADCT -301 is a sterile formulation containing PBD- conjugated HuMax- TAC (DAR ≥1),  
HuMax -TAC (DAR = 0) , and SG3249.  It is provided pre -formulated in 10 mL glass vials 
containing approximately 30 mg ADCT -301 per vial (deliverable volume 5.4 mL at 
6 mg/mL). 
6.7 Management of Clinical Supplies  
6.7.1 Study Drug Packaging and Storage  
ADCT -301 will be supplied in a labeled 10 mL stoppered glass vial  and shipped by 
Fisher  Clinical Services to the  investigational site .  Once the package arrives, the receiving 
site pharmacy will complete the enclosed procedures to  acknowledge receipt.   
All study drugs must be stored in a secure area ( e.g., a locked cabinet).  ADCT -301 should be 
protected from light and stored frozen (–65°C or below ).  ADCT -301 should be thawed 
under ambient conditions .  After the vials have been completely thawed, they should be 
gently mixed by swirling to ensure homogeneity and visually inspected before use .  
The appropriate quantity of ADCT -301 will be removed from the vial with a syringe and 
diluted into a 50 mL IV bag containing 5% dextrose in water (D5W).  The amount of the 
product to be diluted will depend on the dose level and the mass of the patient.  Once the 
ADCT -301 has been transferred , the bag should be mixed to ensure homogeneity of the 
dosing solution.  The contents of the IV bag will then be administered to the patient with a 
dosing pump per institutional guidelines for intravenous fluid (IVF) administration .   
Additional instructions regarding study drug handling, storage, and preparation are included 
in the pharmacy manual. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 44 6.7.2 Study Drug Accountability  
The Investigator will maintain accurate records of receipt of all study drugs, including dates 
of receipt .  In addition, accurate records will be kept regarding when and how much study 
drug is dispensed and used by each patient in the study.  Reasons for departure from the 
expected dispensing regimen must also be recorded .  All study drugs will be reconciled and 
retained or destroyed according to applicable regulations. 
6.8 Overdose Management 
An overdose is any dose of study treatment given to a patient that exceeds the dose described 
in the protocol.  Any overdose, with or without associated AEs, must be promptly reported to the Sponsor .  There are no data available to determine what effects and whether effects of  an 
overdose can be reversed .  Symptomatic treatment and standard supportive care measures for 
the management of this toxicity should be applied. 
6.9 Treatment Compliance 
Administration of the study treatments will be performed by the Investigator or a qualifi ed 
designee; therefore, compliance will be verified by the study drug administration information.  
6.10 Concomitant Treatment 
All medications used within 14 days prior to Day 1 and during the treatment period are to be 
recorded in the eCRF .  Concomitant medicat ion information  will be collected for 30 days 
following the patient’s last dose of ADCT -301.  This will include all prescription drugs, 
herbal products, vitamins, minerals, and over -the-counter medications .  Any changes in 
concomitant medications will also  be recorded  in the patient’s eCRF . 
6.10.1  Prohibited During Study  
• Other anticancer therapy , with the exception of hormonal therapy for maintenance 
treatment of breast and prostate cancer . 
• Radiation therapy is prohibited during the first cycle of therapy.  After the first cycle, 
radiation is permitted for palliative use only if documented radiographic disease progression is ruled out first. 
• Other investigational agents. 
• Chronic treatment with prednisone ≥40 mg/day or equivalent. 
• Live vaccines. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 45 6.10.2  Permitted During Study  
After confirmation and documentation of eligibility, supportive care treatments 
(tran sfusions, etc.) can be prescribed as medically appropriate.  Note: hematopoietic growth 
factors are permitted  per American Society of Clinical Oncology guidelines ; however, 
prophylactic use of growth factors is not allowed during the first treatment cycle .  
If Grade  2 or higher infusion- related hypersensitivity reactions are observed in a patient at 
any time during the study, this patient must receive prophylactic treatm ent with all 
subsequent dosing as per Section 6.2 . 
Concomitant steroid use is permitted as follows:  
• Replacement doses of steroids for patients with adrenal insufficiency  
• Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular 
injection)  
Patients scheduled to receive ADCT -301 are to be administered prophylactic steroid  
treatment as follows , unless contraindicated :  
Dexamethasone 4 mg PO BID  
• Day -1 (day prior to dosing – if possible) 
• Day 1 (day of dosing; give at least 2 hours prior to administration when  not given the 
day before ; otherwise any time prior to administration ) 
• Day 2 (day after dosing) 
Note:  prophylaxis for hypersensitivity will supersede stipulations on dexamethasone 
prophylaxis. 
In addition, spironolactone, at standard doses, may be instituted at any time for patients with 
weight gain greater than 1 kg (2.2 pounds) from Cycle 1 Day 1, new or worsening edema , 
and/or new or worsening pleural effusion.  The dose of spironolactone should be titrated as clinically indicated.  Additional diuretic support may be added if there is further increase in weight, edema or pleural effusion.  
Any concomitant medication deemed necessary for the welfare of the patient during the  
study may be given at the discretion of the Investigator. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 46 6.10.3   Diagnostic, Work-up, and Management of 
Polyradiculopathy/Guillain -Barr é Syndrome 
It is recommended  starting management of polyradiculopathy/ GBS  with either  intravenous 
immunoglobulin ( IVIg) 0.4 g/kg/day for 5 days or plasma exchange (PLEX) once the 
diagnosis of polyradiculopathy/ GBS has been considered by a neurologist ; this would be  at 
CTCAE Grade  2 symptoms for neuropathy or Score 1 as per GBS disability scale 
(Appendix 13.7).  
Diagnostic workup should include: 
• Neurology consultation 
• MRI spine with and without contrast to rule out compressive lesion and evaluate for 
nerve root enhancement or thickening 
• Electrodiagnostic studies (nerve conduction studies) 
• Pulmonary function tests  
• Lumbar puncture: CSF typically has albuminocytologic dissociation with protein elevation disproportionate to WBC —although note that CSF WBC are often elevated 
in GBS associated with immune checkpoint inhibitors 
• Serum antibody testing for GBS (ganglioside antibodies) when possible 
Management includes:  
• IVIg or PLEX as above  
• If IVIg and/or PLEX do not result in improvement, consider using steroids
14 
• Admission  to inpatient unit with capability for rapid transfer to ICU -level monitoring  
• Frequent focused neurological examination (at least twice daily)  
• Frequent pulmonary function monitoring 
• Monitoring for autonomic dysfunction 
• Non-opioid management of neuropathic pain  
• Treatment of const ipation/ileus  
• Anticoagulation 
• Physical therapy 
 
  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 47 7 Study Assessments and Procedures 
Patients  will undergo the procedures at the time points specified in schedule of events  
(Appendix 13.1) . 
7.1 Efficacy Assessments  
Disease assessments will occur every other cycle for the first 2 evaluations (6 weeks [end of 
Cycle 2 ±1 week] and 12 weeks  [end of Cycle 4 ±1 week] ), and every third cycle  
(every  9 weeks  [e.g., end of Cycles 7, 10, 13, etc., ±1 week] ) thereafter until progression or 
more frequently, if clinically indicated .  Assessments may be performed within ± 1 week of 
the required timepoint and response assessment must be available prior to initiation of dosing 
at the subsequent cycle.  
In case of dose delays, disease assessment should be maintained at the frequencies defined 
above and response assessment is required prior to resumption of ADCT -301 dosing 
(only if the interval from last scan is ≥ 6/9 weeks, as applicable) to rule out disease 
progression. 
Tumor response wi ll be determined by the Investigator, based on  the 2014 Lugano 
Classification Criteria (Appendix 13.2) and Global Response Score Grading Scales for CTCL 
(Appendix 13.3) .  Images will be obtained according to local site imaging requirements .  
Images will be required to be submitted for a central/independent review  for Part 2 .  
Submission instructions for the central/independent review will be provided in a separate 
manual. 
7.2 Pharmacokinetic and Pharmacodynamic Assessments 
Blood samples (5 mL draw) will be collected for PK assessment processed according to the 
instructions provided by the bioanalytical laboratory to the clinical sit es.  The concentration 
versus time profile of total antibody HuMax -TAC, PBD- conjugated HuMax -TAC and free 
warhead SG3199 in serum will be determined centrally in Cycles 1 and 2.  
In Cycles 1 and 2, whole blood samples for analysis of PK parameters will be collected at the 
following times: before the start of the ADCT -301 infusion, end of the infusion, and at 1, 3, 6, 
24, 48, 96, 168 (Day 8), and 336 hours (Day 15) after the end of the ADCT -301 infusion  
(Appendix 13.1.2) .  In all subsequent cycles, PK blood samples will be collected before the 
start of the ADCT -301 infusion, at end of the infusion, at End of Treatment  (EOT ), and 
12 weeks following the last ADCT -301 infusion. Additional PK /biomarker blood samples 
will be collected, at the discretion of the Investigator, during any visit where toxicity is 
observed.  All PK samples will be evaluable as long as the actual collection times are 
recorded.  
Please see Appendix 13.1.2 for details on timing windows for blood sample collection  for all 
PK and pharmacodynamic assessments.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 48 Antidrug (ADCT -301) antibodies will be measured centrally at the following times in serum: 
before the start of each ADCT -301 infusion, at EOT , at 12 weeks  following the last 
ADCT -301 infusion, and optionally in PK samples if needed. 
 
 
 
  
  
  
  
  
 
 
  
 
  
7.3 Safety and Tolerability Assessments  
Safety will be assessed based  on AEs, SAEs,  treatment discontinuations due to AEs , DLTs , 
hematology, biochemistry , coagulation panel, pregnancy testing (for women of child-bearing 
potential) and urinalysis  test results.  Adverse events will be graded according to CTCAE 
Version  4.0.  Additional safety assessments include periodic 12- lead ECG recordings, 
physical examination, vital sign measurements, and ECOG performance status.  A schedule 
of all assessments, including safety, is provided in Appendix 13.1.1. 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 49 7.3.1 Dose -Limiting Toxicities and Dose -Escalation Scheme 
7.3.1.1  Definition of Dose -Limiting Toxicities 
A DLT is defined as any of the following events, except those that are clearly due to 
underlying disease or extraneous causes: 
• A hematologic DLT is defined as (not applicable for ATLL patients) : 
o Grade 3 or 4 febrile neutropenia or neutropenic infection. 
o Grade 4 neutropenia lasting > 7 days. 
o Grade 4 thrombocytopenia. 
o Grade 3 thrombocytopenia with clinically significant bleeding, or Grade  3 
thrombocytopenia requiring a platelet transfusion. 
o Grade 4 anemia. 
• For ATLL patients, a hematologic DLT is defined as:  
o Any Grade 4 neutropenia lasting ≥ 42 days from the start of the cycle in the absence 
of evidence of residual leukemia . 
o Grade 3 or higher event of thrombocytopenia or a Grade 4 anemia, with a 
hypocellular bone marrow lasting for ≥ 42 days from the start of the cycle, in the 
absence of  evidence of residual leukemia (i.e., with <5% malignant cells).  
• A non-hematologic DLT is defined as: 
o Grade 4 tumor lysis syndrome (Grade 3 TLS will not constitute DLT unless it leads to 
irreversible end -organ damage). 
o Grade  3 or higher (including nausea, vomiting, diarrhea, and electrolyte imbalances 
lasting ≥ 48 hours despite optimal therapy [excluding all grades of  alopecia]).  
o Grade 3 or higher hypersensitivity reaction  (regardless of premedication ) 
(Appendix 13.4). 
o Skin ulceration ≥ Grade  2. 
o Peripheral sensory or motor neuropathy ≥ Grade 2. 
Note:  The DLT period for dose escalation will be  1 cycle; however, the adaptive 
dose- escalation algorithm will incorporate cumulative DLTs occurring through Cycle 3 .  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 50 7.3.1.2  Safety Oversight by the Dose Escalation Steering Committee 
A DE SC will be responsible for safety monitoring and overall supervision of the study.  
Membership of the DE SC will include: 
• Medical monitor(s)/Pharmacovigilance representative(s) ( Sponsor and/or designee)   
• Investigator(s) from each participating site  
• Biostatistician(s)  
• Ad-hoc members (e.g., project manager, study coordinators, regulatory representatives, 
etc.) 
In general, the DESC  will make any substantial decision s regarding the conduct of the study, 
such as: 
• Monitor the safety  of the study and review its progress at monthly intervals  or more 
frequent intervals as required .  
• In accordance with the CRM ( Appendix 13.5), determine dose levels to be administered 
and the MTD based on assessment of safety findings and determination of DLTs.  
• While the DESC  cannot dictate dose level(s) higher than those prescribed by the CRM, 
the medical judgment of the DESC will supersede the statistical parameters of the CRM.  
• Approve any amendments or administrative changes to the protocol, when required. 
Each DESC  meeting and the decisions made will be documented in writing and provided to 
all participating DESC members and Investigators .  Meeting documents may be submitted to 
IRBs/IECs or competent authorities according to institutional or local requirements .  
Dose escalation will be conducted according to a CRM , as described in Appendix 13.5.   
The first patient at each new dose will be monitored for any AEs for 7 days before 
proceeding with dosing for second patient.  
Durin g dose escalation, the DESC  may expand enrollment at doses below the current dose 
level being evaluated as part of the dose escalation process.  Patients may only be added to 
the lower doses provided there is at least 1 patient with an efficacy evaluation showing stable 
disease.  No more than 10 patients in total can be treated at any dose level unless at least 3 of the 10 patients have documented partial  response or better using the 2014 Lugano 
Classification criteria
2 or other appropriate measures of response ( Appendix 13.3). 
The DESC will be maintained d uring Part 2 ( expansion) of the study to continue to monitor 
and evaluate pat ient safety .  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 51 7.3.2 Adverse Events 
7.3.2.1  Definitions  of Adverse Events  
The Investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance. 
An AE  is defined  as any untoward medical occurrence in a patient enrolled into this study 
regardless of its causal relationship to study drug .  Patients  will be instructed to contact the 
Investigator at any time after the patient signs the ICF  if any symptoms develop. 
A treatment -emergent AE (TEAE) is defined as any event not present before exposure to 
study drug or any event already present that worsens in either intensity or frequency after 
exposure to study drug. 
A serious adverse event  (SAE ) is defined as any event that results in death, is immediately 
life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, 
results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect .  Hospitalization for e lective procedures or for protocol compliance is not considered 
an SAE.  
Important medical events that may not result in death, be life threatening, or require hospitalization may be considered SAE s when, based upon appropriate medical judgment, 
they may j eopardize the patient or may require medical or surgical intervention to prevent 
1 of the outcomes listed in this definition .  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
7.3.2.2  Eliciting and Documenting Adverse Events 
All AEs  will be assessed from the time the patient signs the ICF until 84 days (12 we eks) 
after the last dose of study drug, or initiation of new  anticancer treatment. 
Any S AEs that occur > 84 days (12 weeks) after the last dose of study drug do not need to be 
reported unless the Investigator considers the event to be related t o study drug. 
At every study visit, patients  will be asked a standard  non-leading question to elicit any 
medically related changes in their well-being.  They will also  be asked if they have been 
hospitalized, had any accidents, used any new medications, or changed concomitant medication regimens (both prescription and over-the-counter medications).  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 52 In addition to patient observations, AEs will be documented from any data collected on the 
AE page of the eCRF  (e.g., clinically significant changes in  laboratory values, physical 
examination, ECG changes , etc. ) or identified from review of other documents that are 
relevant to patient  safety.  
7.3.2.3  Reporting Adverse Events 
All AEs reported or observed during the study will be recorded on the AE page of the eCRF .  
Information to be collected includes drug treatment, dose, event term inology, date of onset, 
CTCAE Version 4.0 assessment of severity and relationship to study drug, date of resolution 
of the event, seriousness, any required treatment or evaluations, and outcome.  With the 
exception of disease progression, AEs resulting from concurrent illnesses, reactions to 
concurrent illnesses, and reactions to concurrent medications  also must be reported.  All AEs 
will be followed to adequate resolution .  CTCAE Version  4.0 will be used t o grade all AEs.  
The CTCAE includes 5 grades (1  to 5), with  Grade  5 being death. 
Any AE that meets SAE criteria ( Section  7.3.2.1) must be reported to the contract research 
organization ( CRO) immediately (i.e., within 24 hours after the time site personnel first learn 
about the event ).  The following contact information is to be used for SAE reporting: 
   
  
  
 
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 53 7.3.2.4  Assessment of Severity 
Adverse events are graded according to CTCAE Version  4.0.  For events not included in the 
CTCAE criteria, the severity of the AE is graded on a scale of 1 to 5 as follows:  
1: Mild; asymptomatic or mild sympt oms; clinical or diagnostic observations only; 
intervention not indicated 
2: Moderate; minimal, local or  noninvasive intervention indicated; limiting 
age-appropriate instrumental ADLa 
3: Severe or medically significant but not immediately life  threatening; hospitalization or 
prolongation of hospitalization indicated; disabling; limiting self -care ADLb 
4: Life-threatening consequences; urgent intervention indicated 
5: Death related to adverse event  
a Instrumental activities of daily living (ADL) refer t o preparing meals,  shopping for groceries or clothes, 
using the  telephone, managing money, etc.  
b Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, 
and not bedridden .   
Changes in the severity of an AE should be documented to allow an assessment of the 
duration of the event at each level of intensity to be performed.  Adverse events characterized 
as intermittent do not require documentation of onset and duration of each episode. 
7.3.2.5  Assessment of Causa lity 
The Investigator ’s assessment of an AE’s relationship to study drug is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
eCRF .  All adverse events, regardless of assessment of causality, are rep orted in the eCRF.   
All SAEs  considered at least possibly related to the study drug will be considered 
unexpected; and therefore , reported as Suspected Unexpected Serious Adverse Reaction s 
(SUSARs ). 
7.3.2.6  Follow -up of Patients Reporting Adverse Events 
All AEs m ust be reported  in detail on the appropriate page of the eCRF and followed to 
satisfactory resolution , until the Investigator deems the event to be chronic or not clinically 
significant , or until the patient is considered to be stable.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 54 7.3.3 Pregnancy 
Any pregnancy that occurs during study participation must be reported using a clinical study 
Pregnancy Report F orm.  To ensure patient safety, each pregnancy must be rep orted as 
described for reported AEs in Section 7.3.2.3, upon learning of its occurrence .  
The pregnancy must be followed to determine outcome (including spontaneous miscarriage, 
elective termination, normal birth, or congenital abnormality) and status of mother and child, 
even if the patient  was discontinue d from the study.  The outcome of the pregnancy will be 
reported on the Pregnancy Outcome Form.  Spontaneous miscarriage s must be reported as an 
SAE.  
Any SAE occurring in association with a pregnancy brought to the Investigator ’s attention 
after the patien t has completed the study  and considered by the Investigator as possibly  
related to the study treatment must be promptly reported ( Section 7.3.2.3).  
7.3.4 Clinical Laboratory Analyses 
Samples will be collected at the time points specified in Appendix 13.1.  
Any clinically significant abnormal laboratory test results are to be recorded as AEs or SAEs 
per CTCAE Version 4.0. 
7.3.4.1  Hematology  
Complete blood count (CBC) include s WBC wi th a 5-part differential, platelet count, 
hemoglobin, hematocrit, and ANC . Coagulation panel includes prothrombin time (PT) 
expressed in seconds, International Normalized Ratio (INR) , and partial  thromboplastin time 
(PTT) .  Patients taking coumarin -derivat ive anticoagulants should be monitored closely and 
their anticoagulant dose adjusted as needed.  
7.3.4.2  Biochemistry  
Biochemistry includ es alanine aminotransferase, aspartate aminotransferase, 
gamma -glutamyl transferase, alkaline phosphatase, amylase, lipase, total bilirubin, sodium,  
potassium, calcium, magnesium, blood urea nitrogen or urea,  carbon dioxide/bicarbonate, 
chloride, creatinine, creatine phosphokinase, total protein, albumin, glucose, triglycerides, 
total cholesterol, phosphorus, and lactate dehydroge nase.  At Day 1 of each cycle, 
biochemistry will include creatinine clearance (calculated using the Cockcroft and Gault 
1976 formula). 
7.3.4.3  Urinalysis  
Urinalysis analytes will include pH, protein, specific gravity, glucose , ketones, bilirubin , 
nitrite s, and occult blood.  The urinalysis may be performed using a urine dipstick. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 55 7.3.4.4  Additional Renal Function Studies  
Urine will be collected for testing of biomarkers suggestive of potential renal injury 
(aquaporin- 2, calbindin D28, and clusterin).  Analysis of this addi tional urine sample will be 
performed at a central laboratory  (instructions provided in the L aboratory Manual). 
7.3.4.5  Additional Microbiological Serological studies 
Patients will be regularly examined and asked  whether they have been suffering from an 
infection during their participation in the trial. If there is a reasonable suspicion that such 
infection could have been caused by one of the pathogens listed below, appropriate microbiological workup must be conducted. Should such workup indicate that infection wa s 
indeed caused by one of the se microorganisms, re- dosing must be delayed so that there is a t 
least a four- week  window between symptom resolution and the next dose of ADCT-301. 
Pathogens of interest are: HSV1, HSV2, VZV, EBV, CMV, measles, Influenza A, Zika virus, 
Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, and enterovirus D68.  
7.3.5 Electrocardiograms 
On Day 1 of Cycle s 1 and 2, a 12-lead ECG will be performed before the start of the 
ADCT -301 infusion, at completion of infusion and at 3 hours and 24 hours (Day 2) after the 
end of infusion.  ECGs should occur within 10% of nominal time  (e.g., 3 hours ± 18 minutes) .  
Any abnormalities , including those that worsen from baseline, believed to be clinically 
significant in the medical and scientific j udgment of the Investigator are to be recorded as 
AEs or SAEs . 
Measurement of the QTc interval may be obtained according to the formula used by the  
institution, however, the Fridericia formula is preferred.5  The same formula used to confirm 
eligibility must be applied within a patient for the duration of the study.     
7.3.6 Physical Examination  
Physical examination s will include a complete review of body systems , including whole 
body skin assessmen t.  Whole body s kin assessment does not have to be performed by a 
dermatologist; however, any unexplained lesion will be referred to a dermatologist for further 
evaluation and biopsy if clinically warranted.  Physical examination will also include a 
neurological examination of strength, sensation, and deep tendon reflexes; unexpected 
findings will be referred to a neurologist for further evaluation. Height will be measured at 
the Screening Visit (Day –28 to –1) and patients are advised to monitor their weight on a 
daily basis  because new or worsening edema and / or new or worsening pleu ral effusion have 
been observed.  Patients should inform their Investigator if their weight increases by more 
than 1 kg (2.2 pounds) after Cycle  1 Day 1.   
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 56 The examination must include a determi nation if the patient has had any infection.  At the 
discretion of the investigator, evaluation of any reported infection must be conducted to rule 
out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the exclusion criteria.  
Any clinically significant abnormalities , including those that worsen from baseline, are to be 
recorded as AEs or SAEs . 
7.3.7 Vital Sign Measurements 
Vital sign measurements will include arterial blood pressure, heart rate, respiratory rate, and temperature .  Any clinically significant abnormalities, including those that worsen from 
baseline, are to be recorded as AEs or SAEs.  
7.3.8 Eastern Cooperative Oncology Group Performance Status  
The patient’s performance status will be assessed  according to the time points in the schedule 
of events ( Appendix 13.1) using the ECOG performance status grades9 below: 
0: Fully active, able to carry on all pre -disea se performance without restriction  
1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work 
2: Ambulatory and capable of all self-care but unable to carry  out any work activities.  Up and 
about more than 50% of waking hours  
3: Capable of only limited self -care, confined to bed or chair more than 50% of waking hours  
4: Completely disabled .  Cannot carry on any self -care.  Totally confined to bed or chair  
5: Dead  
7.4 Sample Handling, Storage , and Shipment  
Detailed instructions for  central laboratory sample collection, labeling, processing, storage, 
and shipping will be provided to the site in the central Laboratory Manual.   
During the study, whole blood sampl es will be collected for PK,  ADA,  pharmacodynamics 
PBMC subset analysis), and safety analyses (clinical chemistry,  
, and hematology) . 
For PK,
 ADA,  blood samples are to be collected and 
processed on site according to the Laboratory  Manual . The result ing serum samples should 
be aliquoted and stored frozen at ≤ -70°C until shipment.  Each sample tube must  be clearly 
labeled with the following information: study number, study center number, patient number, 
tube identification, and the sample collection time point (by day and hour), when necessary.  
Serum and urine samples are to be packed in sufficient dry ice  and shipped from the study 
center to the central laboratory .  Once lab eled, samples should be stored at ≤ -70°C until 
shipment .  Samples should be shipped according to the sample shipment schedule provided 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 57 in Laboratory Manual.  
  
 
The clinical chemistry and hematology samples, which should not be frozen, a re transferred  
at ambient  temperature to local laboratories.   
For the PBMC subset analysis, whole blood is to be collected and shipped as per the central 
Laboratory  Manual directly to the testing laboratory for immediate processing.  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 58 8 Statistical and Analytical Plan  
Full details of the analysis plan, including a more technical and detailed elaboration of the 
statistical analyses will be provided in the Statistical Analysis Plan (SAP).   
 
8.1 Safety Endpoints  
Safety will be assessed based on AEs , SAEs  (graded using CTCAE v4.0) , treatment 
discontinuations due to AEs, DLTs,  hematology, coagulation panel, biochemistry, pregnancy 
testing (for women of child -bearing potential) and urinalysis test results .  Addi tional safety 
assessments include periodic 12 -lead ECG recordings, physical examinations , vital sign 
measurements, and ECOG performance status.  A schedule of the safety assessments is 
provided in Appendix 13.1.1. 
8.2 Study Endpoints  
8.2.1 Primary Endpoints 
The primary objectives for Part 1 (dose escalation) and Part 2 (expansion) of the study are: 
• Determine the safety of ADCT -301 by assessing DLTs and determining the MTD in 
Part 1 (dose- escalation).  
• Determine the recommen ded dose of ADCT-301 for Part 2 (expansion). 
• Evaluate the safety and tolerability of ADCT -301 in patients with relapsed/refractory  
lymphoma in Part 2 (expansion). 
8.2.2 Secondary Endpoints  
The following secondary endpoints will be determined in Part 1 and Part 2: 
• Evaluate r esponse to ADCT -301 using the Lugano Classification Criteria (2014)  
(Appendix 13.2) and Global Re sponse Score  Grading Scales for CTCL ( Appendix13.3) 
through the evaluation of complete response (CR), partial response (PR), progressive 
disease (PD), and stable disease (SD) . 
• Characterize PK profile of HuMax- TAC (total antibody; drug -to-antibody ratio [DAR] 
≥ 0), PBD -conjugated HuMax-TAC (DAR ≥1), and free warhead SG3199 
(see Section  8.6.3). 
• Determine anti- drug antibodies ADA s in blood before, during, and after treatment with 
ADCT -301. 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 59  
 
  
  
  
  
  
   
8.3 Sample Size Calculations  
This is a Phase 1 study with a total s ampl e size of approximately 140 patients .  It is expected 
that Part 1 will enroll a pproximately 80 patients, and Part 2 will enroll a pproximately  
60 patients  (Section 4.1.1 and Section 4.1.2).  
Simulations were performed assuming scenarios with different dose -toxicity relationships to 
evaluate the sample size for Part 1.  
Patients will be enrolled in Part 2 of the study in cohorts of approximately 10.  The cohort s 
will be enrolled at the dose level recommended in Part 1 .   
The DESC will make recommendations with regard to the intended differences between 
these cohorts, e.g. tumor subtypes, dosing regimen or dose levels, as well as the number of these cohorts, taking into ac count the limit on the overall number of patients as specified 
above and safety/efficacy data observed up to that decision point. 
8.4 Analysis Sets 
Five analysis sets will be used in this study:  
• The Safety  analysis set consists of  all patients who receive stud y drug 
• The DLT- evaluable analysis set consists of all patients in Part 1 who receive study drug 
and excludes  patients who discontinue from the study during the first 21- day cycle 
without experiencing a DLT . 
• The Efficacy analysis set will consist of all patients with valid baseline data who 
receive at least 2 doses of study drug or who have documented progression of disease at any time after the first dose of study drug.  Patients who do not have a post baseline assessment due to early clinical progression, toxicity, or death will also be included.  
• The PK analysis set  consists of all  patients who  receive study drug and have sufficient 
concentration data for PK analysis.  

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 60 • The pharmacodynamic analysis set consists of all patients who receive study drug and 
have sufficient concentration data for pharmacodynamic analysis. 
8.5 Description of Subgroups to be Analyzed 
Subgroup analyses, if planned, will be described in the SAP . 
8.6 Statistical Analysis  Methodology  
8.6.1 Efficacy Analysis  
8.6.1.1  Overall Response Rate  
Overall response rate is defined as the proportion of patients with best overall response of PR 
or CR at the time each patient discontinues treatment with ADCT -301 ( Appendix 13.2, 
Appendix 13.3).  
8.6.1.2  Duration of Response  
Duration of response  will be defined among responders  (CR or PR)  as the time from the  
earliest date of first response until the first date of either  disease progression or death due to 
any cause.  The date of disease progression will be defined as the earliest date of disease 
progression as assessed by the Investigator using the 2014 Lugano Classification for response 
for Hodgkin and Non- Hodgkin Lymphoma2 (Appendix 13.2) or Global Response Score 
criteria for disease progression for CTCL ( Appendix 13.3).  For patients who have not 
progressed or who have died at the time of the analysis, censoring will be performed using 
the date of the last adequate disease assessment .  In addition, patients with disease 
progression or death after an extended loss to follow -up will be censored at the date of the 
last adequate disease assessment prior to the extended loss to follow -up.  Further details on 
censoring rules will be outlined in the SAP.  
8.6.1.3  Overall Survival  
Overall survival will be defined as the time  from the beginning of ADCT -301 treatment until 
death due to any cause.  For patients who have not died at the time of the analysis, censoring will be performed using the date the patient was last known to be alive .  Further details on 
censoring rules will  be outlined in the SAP.  
8.6.1.4  Progression- Free Survival  
Progression- free survival will be defined as the time from first dose of study drug until the 
first date of either disease progression or death due to any cause.  The date of disease 
progression will be de fined as the earliest date of radiological disease progression as assessed 
by the Investigator using the 2014 Lugano Classification for response for Hodgkin and 
Non-Hodgkin Lymphoma2 (Appendix 13.2) or Global Response Score  criteria for disease 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 61 progression for CTCL ( Appendix 13.3).  Patients with  stable disease / without  disease 
progression, or patients with death after an extended loss to follow -up, will be censored at the 
date of the last adequate disease assessment prior to the extended loss to follow -up.  
Further details on censoring rules will be outlined in the SAP. 
8.6.2 Safety Analyses  
8.6.2.1  Analyse s of Adverse Events  
An AE will be considered to be a TEAE if it begins or worsens on or after first dose date and 
before last dose date until 84 days (12 weeks) .  Planned s ummaries of TEAEs are detailed in 
the statistical analysis plan and will include: 
• All TEAEs . 
• All s erious TEAEs . 
• All treatment-r elated TEAEs . 
• All treatment-r elated serious TEAEs . 
• All TEAEs r esulting in study drug discontinuation. 
• All DLTs . 
• Other AE analyses of interest will be specified in the SAP .  
The incidence of deaths and the primary cause of death will be summarized.  
8.6.2.2  Clinical Laboratory Results 
Clinical hematology , biochemistry , and urinalysis  data will be summarized at each scheduled 
assessment .  Numeric hematology and biochemistry results will be summarized using change 
from baselin e.  All results will be summarized using shift from baseline .  Shifts for clinical  
laboratory results that can be graded according to CTCAE Version 4.0 will be summarized 
by CTCAE grade.  Shifts for other numeric laboratory results will be by high/normal/low 
flag.  Shifts for all other laboratory result s will be by normal/abnormal flag. 
Summaries by visit will include data from scheduled assessments, and all data will be reported according to the nominal visit date for which it was recorded .  Unscheduled da ta 
will be included in “worst case post baseline” summaries, which will capture a worst case 
across all scheduled and unscheduled visits after the first dose of study treatment .  
Further details will be provided in the SAP. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 62 8.6.2.3  Additional Safety Assessments  
The results of scheduled assessments of vital signs, physical examinations, 
ECOG performance status, and 12 -lead ECG s will be summarized .  All data will be reported 
according to the nominal visit da te for which it was recorded (i.e., no visit windows will be  
applied) .  Unscheduled data will be included in “ wors t case”  summaries, which will capture a 
worst case across all scheduled and unscheduled visits after the first dose of study treatment .  
All data will be listed .  Further details will be provided in the  SAP. 
8.6.3 Pharmacokinetic  and Pharmacodynamic  Analyses  
In Cycles 1 and 2, whole blood for PK samples will be collected at the following times: 
before the start of the ADCT -301 infusion, at the end of infusion and at 1, 3, 6, 24, 48, 96, 
168 (Day 8) and 336 hours (Day 15) after the  end of the ADCT -301 infusion. 
In all subsequent cycles PK  blood samples will be collected  before the start of the 
ADCT -301 infusion, at end of infusion, at EOT,  and finally 12 weeks  following the last 
ADCT -301 infusion. 
PK endpoints for HuMax- TAC, PBD- conjugated HuMax- TAC, and free warhead SG3199 
will be evaluated for all patients using noncompartmental  analysis and may include: 
maximum concentration (C max), time to maximum concentration ( Tmax), area under the 
concentration -time curve from time zero to the last quantifiable concentration (AUC 0-last), 
area under the concentration -time curve from time zero to the end of the dosing interval 
(AUC 0-τ), area under the concentration -time curve from time zero to infinity (AUC 0-∞), 
accumulation index (AI), volume of distribution at steady- state (V ss), mean residence time 
(MRT), terminal elimination phase rate constant (λz), apparent terminal half- life, CL, and Vz.  
Data for PK parameters will be summarized in tables and individual data will be listed.  
In addition, pharmacodynamic and ADA analyses will be performed to include:  
• PBMC subset analysis in Part 2 of the study by flow cytometry in whole blood  
 
   
   
  
   

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 63 8.6.4 Study Drug Exposure 
Study drug exposure will be summarized by dose level and overall .  Duration of  treatment, 
total number of cycles dosed, and total dose received will be summarized .  The number of  
patients dosed by cycle will also be summarized using frequency counts and percentages.  
Duration of treatment will be calculated as date of last dose of st udy drug – date of first dose 
of study drug + 1. 
8.7 Data Quality Assurance 
Steps to be taken to ensure the accuracy and reliability of data include the selection of a 
qualified Investigator  and appropriate study site, review of protocol procedures with the 
Investigator  and associated personnel before the study and periodic monitoring visits by the 
clinical research associate.  Written instructions will be provided for collection, preparation, 
and shipment of blood and plasma samples. 
The eCRFs will be provided to the clinical contact and the clinical research associate will 
review them with site personnel.  
The clinical research associate will review eCRFs for accuracy and completeness by remote 
monitoring, during on- site monitoring visits , and after transmissio n to the Sponsor ; any 
discrepancies will be resolved with the Investigator or designee, as appropriate .  After entry 
of the data into the clinical study database they will be verified for accuracy.  
8.7.1 Data Management 
As part of the responsibilities assumed by participating in the study, the Investigator agrees 
to maintain adequate case histories for the patients treated as part of the research under this 
protocol .  The Investigator agrees to maintain accurate eCRFs and source documentation as 
part of the case histories .  These source documents may include laboratory reports , 
ECG strips , and patient diaries . 
Investigative site personnel will enter patient data into Medidata Rave.  The analysis data sets 
will be a combination of these data and data from other sources ( e.g., laboratory data).  
Clinical data management will be performed in acco rdance with applicable CRO standards  
and data cleaning procedures to ensure the integrity of the data ( e.g., removing errors and 
inconsistencies in the data) .  Adverse events will be coded using the Medical Dictionary for 
Regulatory Activities  Version 16.0.  Concomitant medications will be coded using 
WHO  Drug  Dictionary  01 June 2013. 
After database lock, each study site will receive information  about all of their site -specific 
eCRF data as entered into electronic data capture system  for the study, including full 
discrepancy and audit history .  Additionally, a copy of all of the study site’s data from the 
study will be created and sent to the Sponsor for storage.  The CRO will ma intain a duplicate 
copy for its records.  In all cases, patient initials will not be collected or transmitted to the 
Sponsor. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 64 9 Ethics  
9.1 Independent Ethics Committee or Institutional Review Board 
Federal regulations and the International Co uncil for  Harmonis ation (ICH) guidelines require 
that approval be obtained from an institutional review board (IRB)/ independent ethics 
committee ( IEC) before participation of human patients  in research studies.  Before study 
onset, the protocol, informed consent, advertisements to be used for the recruitment of study 
patients , and any other written information regarding this study to be provided to the patient  
or the patient ’s legal guardian must be approved by the IRB/IEC.  Documentation of all 
IRB/IEC approvals and of the IR B/IEC compliance with the current version of  
ICH harmonis ed tripartite guideline E6: Good Clinical Practice (GCP) will be maintained by 
the site and will be available for review by the Sponsor or its designee. 
All IRB/IEC approvals should be signed by the IRB/IEC chairman or designee and must identify the IRB/IEC name and address, the clinical protocol by title or protocol number or both, and the date approval or a favorable opinion was granted. 
The Investigator is responsible for obtaining continued review  of the clinical research at 
intervals not exceeding 1 year or otherwise specified by the IRB/IEC.  The Investigator  must 
supply the Sponsor or its designee with written documentation of continued review of the 
clinical research.  
9.2 Ethical Conduct of the Study  
The study will be performed in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, ICH GCP , and all applicable regulations. 
9.3 Patient Information and Consent 
A written informed consent in compliance with IRB/IEC a nd local regulations  shall be 
obtained from each patient before entering the study or performing any unusual or  
non-routine procedure that involves risk to the patient .  An informed consent template may 
be provided by the Sponsor to investigative sites.  If any institution -specific modifications to 
study- related procedures are proposed or made by the site, the consent should be reviewed by 
the Sponsor or its designee or both before IRB/IEC submission .  Once reviewed, the consent 
will be submitted by the Investigator  to his or her IRB/IEC for review and approval before 
the start of the study.  If the ICF is revised during the course of the study, all patients 
on-study must sign the revised form , unless otherwise indicated by the IRB/IEC  
(local or global, as a pplicable) . In such case, the reason for not re -consenting the patient 
should be documented. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 65 Before recruitment and enrollment, each prospective patient or his or her legal guardian will 
be given a full explanation of the study and be allowed to read the approved ICF.  Once the 
Investigator is assured that the patient /legal guardian understands the implications of 
participating in the study, the patient /legal guardian will be asked to give consent to 
participate in the study and that additional  
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 66 10 Investigator’s Obligations  
The following administrative items are meant to guide the Investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating 
procedures, working practice documents , or guidelines .  Changes will be reported to the 
IRB/IEC but will not result in protocol amendments.  
10.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain patient  confidentiality .  All records will be kept in a secure 
storage area with limited access.  Clinical information will not be released without the 
written permission of the patien t (or the patient ’s legal guardian), except as necessary for 
monitoring and auditing by the Sponsor, its designee, the FDA, or the IRB/IEC. 
The Investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other 
unpublished, confidential information disclosed to those individuals for the purpose of the study.  Prior written agreement from the Sponsor or its designee must be obtained for the 
disclosure of  any said confidential information to other parties.  
10.2 Financial Disclosure and Obligations  
Investigators are required to provide financial disclosure information to allow the Sponsor to 
submit the complete and accurate certification or disclosure statements required under 
21 CFR 54  and local regulations.  In addition, the Investigator must provide to the Sponsor a 
commitment to promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. 
Neither the Sponsor nor the CRO is financially responsible for further testing or treatment of 
any medical condition that may be detected during the screening process.  In addition, in the 
absence of specific arrangements, neither t he Sponsor nor the CRO  is financially responsible 
for further treatment of the patient’ s disease.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 67 10.3 Investigator Documentation  
Prior to beginning the study, the Investigator will be asked to comply with the current version 
of ICH E6 8.2 , Title 21  of the CFR , and local regulations  by providing the following 
essential documents, including but not limited to: 
• IRB/IEC approval  
• Original Investigator -signed Investigator agreement page of the protocol  
• Form FDA 1572, fully executed, and all updates on a new fully e xecuted 
Form  FDA  1572 (where applicable)  
• Curriculum vitae for the Investigator and each sub -Investigator listed on 
Form  FDA  1572 (where applicable)  
• Financial disclosure information to allow the Sponsor to submit complete and accurate 
certification or dis closure statements.  In addition, the Investigator s must provide to the 
Sponsor a commitment to promptly update this information if any relevant changes 
occur during the course of the investigation and for 1 year after the completion of the study  
• IRB/IEC -approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided to the patient or legal guardian  
10.4 Study Conduct 
The Investigator agrees that the study w ill be conducted according to the principles of the 
current version of  ICH E6 .  The Investigator will conduct all aspects of this study in 
accordance with all national, state, and local laws or regulations.  Study information from 
this protocol will be pos ted on publicly available clinical study  registers before enrollment of 
patients  begins. 
10.5 Adherence to Protocol  
The Investigator agrees to conduct the study as outlined in this protocol in accordance with 
the current version of ICH E6 and all applicable guidelines and regulations. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 68 10.6 Adverse Events and Study Report Requirements  
By participating in this study, the Investigator agrees to submit reports of SAEs  to the 
Sponsor according to the timeline and method outlined in the protocol.  In addition, the 
Investigator  agrees to submit annual reports to the study site IRB/IEC as appropriate.  
The Sponsor will ensure that all relevant safety information (SAEs and SUSARSs) is 
reported to  the FDA and competent authorities of EU Member States, and to the IEC, 
in accordan ce with current legislation (US 21CFR.316 and EU Directive 2001/20/EC). 
10.7 Investigator’s Final Report  
Upon completion of the study, where applicable, the Investigator should provide the IRB/IEC with a summary of the study outcome and the Sponsor and regulatory authority( ies) with any 
reports required. 
10.8 Records Retention 
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing applic ations in an ICH region or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product .  These documents 
should be retained for a longer period, however, if required by the applicable regulatory requirements or by an agreement with the Sponsor .  It is the responsibility of the Sponsor to 
inform the Investigator /institution as to when these documents no longer need to be retained. 
10.9 Publications 
Data  may be considered for reporting at a scientific meeti ng or for publication in a scientific 
journal .  In these cases, the Sponsor will be responsible for coordination of these activities 
and will work with the Investigator s to determine how the manuscript is written and edited, 
the number and order of authors, the publication to which it will be submitted, and other related issues.  The Sponsor has final approval authority over all such issues.  
Data are the property of the Sponsor and cannot be published without prior authorization 
from the Sponsor, but data and publication thereof will not be unduly withheld. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 69 11 Study Management 
11.1 Monitoring  
11.1.1  Monitoring of the Study  
The clinical monitor, as a representative of the Sponsor , has the obligation to follow the 
study closely.  In doing so, the monitor will visit the Inves tigator and study site at periodic 
intervals, in addition to maintaining necessary telephone and written  contact .  The monitor 
will maintain current personal knowledge of the study through observation, review of study 
records and source documentation, and discussion of the conduct of the study with the Investigator and personnel. 
All aspects of the study will be carefully monitored by the Sponsor or its designee for 
compliance with applicable government regulation with respect to current GCP and current 
standard operating procedures. 
11.1.2  Inspection of Records 
Investigators and institutions involved in the study will permit study -related monitoring, 
audits, IRB/IEC review, and regulatory inspections by providing direct access to all study records.  In the event of an audit, the Investigator agrees to allow the Sponsor , representatives 
of the Sponsor, or a regulatory agency access to all study records.  
The Investigator should promptly notify the Sponsor and the CRO of any audits scheduled by 
any regulatory authorities and promptly forward copies of any audit reports received to the Sponsor. 
11.2 Management of Protocol Amendments and Deviations  
11.2.1  Modification of the Protocol  
Any change  in the study plan requires a protocol amendment .  An Investigator may not make 
any changes to the study without IRB/IEC and Sponsor approval, except those necessary to 
remove an apparent immediate hazard to the patient .  A protocol change intended to 
eliminate an apparent immediate hazard to patient(s) may be implemented immediately, but the c ircumstances of the change must be documented and submitted to the IRB/IEC and to 
the Sponsor for further evaluation .  If the protocol is in need of substantial changes, t he 
Sponsor will amend the protocol and seek approval from the appropriate regulatory 
authority(ies) before implementation .  All a mendments to the protocol must be reviewed and 
approved following the same process as the original protocol before the amended protocol  
can be implemented . 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 70 11.2.2  Protocol Deviations 
The Investigator will make every attempt to avoid deviations from the protocol, except in 
medical emergencies.  In the event of a medical emergency, the Medical Monitor must be 
notified as soon as possible.  The Investigator will inform the governing IRB/IEC of all 
protocol changes issued by the Sponsor in accordance with the IRB/IEC’s established 
procedure. 
11.3 Study Termination  
The Sponsor has every intention of completing the study; however, the Sponsor reserves the 
right to discontinue the study at any time for clinical or administrative reas ons. 
The end of the study is defined as the date on which the last patient  completes the last visit to 
the study site (includes any end of t reatment  visit to the site  and any visit to the site to obtain 
confirmatory scan of response ). 
11.4 Final Report 
Whether the study is completed or prematurely terminated, the Sponsor will ensure that the 
clinical study reports are prepared and provided to regulatory agency( ies) as required by the 
applicable regulatory requirement(s).  
An Investigator will be identified to act as the signatory for  the clinical study report.  
The Investigator will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity to review the complete study results. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 71 12 Reference List  
1. Cairo MS. Coiffier B, Reiter A, and Younes A, on behalf of the TLS Expert Panel .  
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome 
(TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haem  2010, 149: 578–586. 
2. Cheson BD, Fisher RI, Barrington SF, et al . Recommendations for initial evaluation, 
staging, and response assessment of Hodgkin and Non- Hodgkin lymphoma:  The Lugano 
classification . J Clin Onc  2014, 32(27):3059-3068 
3. Rudin CM, Pietanza MC, Bauer TM,  Spigel DR, Ready N, Morgansztern D, Glisson BS, 
Byers LA, Johnson ML, Burris HA, Robert F, Strickland DK, Zayed H, Govindan R, Dylla S, Pend SL . Safety and efficacy of single -agent rovolpituzumab tesirine 
(SC16LD6.5), a delta -like protein 3 (DLL3) -targeted antibody- drug conjugate (ADC) in 
recurrent or refractory small cell lung cancer (SCLC).  J Clin Oncol 34 (2016) (suppl: abstr LBA8505). 
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron. 1976;16(1):31-41. 
5. Friderici a LS. The duration of systole in the electrocardiogram of normal subjects and of 
patients with heart disease. Act Med Scand  1920, 53:469–486.  Translation published in 
2003 in Annals Noninvasive Electrocardiology 8(4):343-351. 
6. Karube K, Aoki R, Nomura Y , e t al. Usefulness of flow cytometry for differential 
diagnosis of precursor and peripheral T -cell and NK -cell lymphomas: analysis of 
490 cases. Pathol Int . 2008;58(2):89-97.  
7. LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion- protein 
(DAB389IL -2) in lymphomas expressing the receptor for interleukin- 2. 
Blood. 1998;91(2):399-405. 
8. Novartis, New Jersey, USA . Prescribing information for Simulect., 2005, accessed at 
https://www.pharma.us.novartis.com/product/pi/pdf/simulect.pdf .  
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the 
Eastern  Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649- 55. 
10. O'Malley DP, Chizhevsky V , Grimm KE, et al. Utility of BCL2, PD1, and CD25 
immunohistochemical expression in the diagnosis of T -cell lymphomas.  
Appl Immunohistochem Mol Morphol. 2014;22(2) :99-104. 
11. Roche Pharmaceuticals, New Jersey, USA. Prescribing Information for Zenapax ., 2005, 
accessed at http://www.gene.com/download/pdf/zenxapax_prescribing.pdf. 
12. Strauchen JA, Breakstone BA. IL -2 receptor expression in human lymphoid lesions. 
Immunohistochemical study of 166 cases. Am J Pathol. 1987;126(3):506-12. 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 72 13. Sejvar JJ, Koohl KS, Gidudu J, Amato A, Bakshi  N, Baxter R, et al, (2011) 
Guillain -Barre syndrome and Fisher syndrome: case definitions and guidelines for 
collection, analysis, and presentation of immunization safety data. Vaccine; 29(3): 
599-612. 
14. Gu Y , Menzies AM, Long GV , Fernando SL, Herkes G (2017) Immune mediated 
neuropathy following checkpoint immunotherapy. J Clin Neurosci. Nov;45:14-17. 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol Amendment 9 
Date of Protocol: 4 January 2019            Page 73 13 Appendices 
13.1 Appendix: Schedule of Events  
The Schedule of Events for study procedures is shown in Section 13.1.1 of this Appendix.  
Timing s for sample collections for assessments of PK, ADA, , and  
are shown in Section  13.1.2. 
 
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019                  Page 74  
13.1.1  Schedule of Study Procedures 
Procedure  Screening  Cycle 1  Cycle 2  Cycles 3 until 
Progress ion/ 
Discontinuation  End of 
Treatment1 Long -term  
Follow -up 
(up to  12 mos)  
Day –28 
to –1 
Day 1 
(±3 days)  
Day 8 
(±1 day)  
Day 15  
(±1 day)  
Day 1 
(±3 days)   
Day 8 
(±1 day)  
Day 15  
(±1 day)  
Day 1 
(±3 days)   
Day 8 
(±1 day)  
Informed consent  X           
Demog raphy  X           
Medical and cancer history2 X           
Pregnancy test  
(β-HCG, serum or urine)  X X3        X  
Tumor tissue collection4 X           
Physical examination, including 
neurological examination and 
whole body skin assessment5 X X6 X X X6 X X X6  X  
Vital signs  X X7 X X X7 X X X7 X X  
Height  X           
Weight  X X6 X X X6 X X X6 X X  
ECOG  Performance status  X X6   X6   X6  X  
Disease assessment8 X       X9  X10 X11 
Hematology12 X X13 X X X13 X X X13 X X  
Coagulation Panel14 X X13   X13   X13  X  
Biochemistry15 X X13 X X X13 X X X13 X X  
Urinalysis 16 X X13 X X X13 X X X13 X X  
Additional renal function studies17  X13 X X X13 X X X13 X X  
12-lead ECG  X X18   X18   X  X  
Sample collection for  
Pharmacokinetic assessments19  X X X X X X X  X X20 
 
            

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019                  Page 75 Procedure  Screening  Cycle 1  Cycle 2  Cycles 3 until 
Progress ion/ 
Discontinuation  End of 
Treatment1 Long -term  
Follow -up 
(up to  12 mos)  
Day –28 
to –1 
Day 1 
(±3 days)  
Day 8 
(±1 day)  
Day 15  
(±1 day)  
Day 1 
(±3 days)   
Day 8 
(±1 day)  
Day 15  
(±1 day)  
Day 1 
(±3 days)   
Day 8 
(±1 day)  
Sample collection for anti -drug 
antibody assessment19  X   X   X  X X20 
Sample collection and shipment for 
PBMC analysis21  X X X X X X   X  
 
            
 
         
    
ADCT -301 administration22  X   X   X    
Prophylactic administrations23  X   X   X    
Adverse events  X X X X X X X X X X X24 
Concomitant medications25 X X X X X X X X X X  
Survival information            X26 
New anti -cancer treatment 
information            X27 
Abbreviations: ANC, absolute neutrophil count; b-HCG, beta human chorionic gonadotropin; CBC, complete blood count; CT, computed tomography; CTCL,  cutaneous T -cell 
lymphoma; ECOG, Eastern Cooperative Oncology Group; ECG, electrocardiogram; FDG, 18F -fluorodeoxyglucose; ; INR, International 
Normalized Ratio; mos, months; MRI, magnetic resonance imaging; mSWAT, modified Severity -Weighted Assessment Tool; NHL, non-Hodgkin lymphoma; PBMC, peripheral 
blood mononuclear cells; PET -CT, positron emission tomography- computed tomography; PT, prothrombin time; PTT, Partial prothrombin time; WBC, white blood cell  
 
 
1  As soon as possible after decision to discontinue the study drug AND prior to initiation of anticancer treatment. 
2  To include a complete history of all surgeries, significant diagnoses, all cancer treatments, and assessment of cardiac risk fact ors. 
3  For women of childbearing potential. Not required if negative screening serum beta -human chorionic gonadotropin pregnancy (β-HCG ) test was obtained 
within 7 days prior to Day 1, Cycle 1.  
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019                  Page 76  
4  Collection of tumor tissue (formalin -fixed paraffin embedded block) for retrospective testing of  protein expression by immunochemistry at a central 
laboratory. Tissue from a recent bio psy is preferred, if available, and/or if patient provides consent for biopsy during screening. Archival tissue taken at any 
prior relapse is acceptable.  
5  Physical examination , including neurological examination and  whole body skin assessment. Whole bod y skin assessment does not have to be performed by a 
dermatologist. Any  unexplained lesion to be referred to a dermatologist for further evaluation and skin biopsy, if clinically warranted.   The examination must 
include a determination if the patient has h ad any infection.  At the discretion of the investigator, evaluation of any reported infection must be conducted to 
rule out infection with a microorganism that may be associated with autoimmune or neurological disease(s) as specified in the  exclusion crit eria. 
6 Not to be repeated on Day 1, Cycle 1 if last performed within 3 days prior to dosing.  
7  On Day 1 of Cycle 1, vital signs (arterial blood pressure, heart rate, respiratory rate, temperature) are measured before the start of the infusion, every 
30 minutes during the infusion, and at the end of infusion (± 15 minutes ). If no clinically significant changes occur during the first infusion, measurements 
are required prior to infusion start, hourly during infusion, and end of infusion for all subsequent i nfusions.  
 For Cycles 1 and 2, patients will be monitored for 4 hours post -infusion with vital signs being measured 1 hour after the end of infusion and at discharge  
(± 15 minutes ). 
8  Screening tumor assessments: PET- CT and diagnostic CT  of the neck/chest/abdomen/pelvis and other areas of known disease or newly suspected disease 
with a clinical examination for lymphoma. Contrast should be used unless contraindicated. Magnetic resonance imaging (MRI) is permitted if diagnostic CT 
is contraindicated. The sam e assessment methods used at Screening should be used for all subsequent assessments. Note : PET -CT is only required at 
screening for FDG -avid, nodal lymphomas (defined as per the Lugano Classification criteria as essentially all eligible histologies except  small lymphocytic 
lymphoma, lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia, mycosis fungoides, and marginal zone NHLs, unless there  is a suspicion of 
aggressive transformation. If PET -CT examination is negative at Screening, subsequent PET -CT is not required. If PET -CT is positive, subsequent 
diagnostic CT and MRI are not needed, unless clinically indicated.  In case of dose delays, response assessment is required prior to resumption of ADCT -301 
dosing (only if the interval from last sca n  i s  ≥  6 / 9  w e e k s ,  a s  a p p l i c a b l e )  t o  r u l e  o u t  d i s e a s e  p r o g r e s s i o n .   
For CTCL patients with disease limited to the skin, disease assessments after screening will be performed using mSWAT; radiological imaging after 
screening for CTCL patients with disease limited to the skin is not required unless clinically indicated . 
9  Disease assessments will be performed within 6 days prior to Day 1 of Cycles 3 and 5 and thereafter every third cycle (i .e., Cycles 8, 11, 14, etc .) until 
disease progression or more freque ntly, if clinically indicated. The same assessment methods used at Screening which identify sites of disease should be 
used uniformly for all subsequent assessments  
10  Patients who already have documented objective disease progression do not need to have a ssessments repeated. Patients who do not already have 
documented objective disease progression will have assessments performed if the most recent disease assessment was greater than 9 weeks prior to the end of treatment visit.  
11  Patients who discontinue  treatment for any reason other than objective disease progression will continue to be followed with scans approximately every 
12 weeks from the last tumor assessment until disease progression, or initiation of new anticancer treatment .  If patient discontin ues treatment for a 
hematopoietic stem cell transplant, the frequency of imaging will be as per the transplant center standard of care.  
12  Hematology: complete blood count ( CBC) to include WBC with 5 -part differential, platelet count, hemoglobin, hematocri t, and ANC.  
13  Sample collection to occur prior to dosing on Day 1 unless the last sample was collected: <24 hours before the start of ADCT 301 infusion on Day 1 of 
Cycle 1, or <72 hours before the start of ADCT -301 infusion on Day 1 of Cycle 2 and subsequ ent cycles.  
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019                  Page 77  
14  Coagulation panel includes prothrombin time (PT) expressed in seconds, International Normalized Ratio (INR), and partial thromboplastin time (PTT).   
15  Biochemistry: alanine aminotransferase, aspartate aminotransferase, gamma- glutamyl transf erase, alkaline phosphatase,  amylase, lipase, total bilirubin, 
sodium, potassium, calcium , magnesium, blood urea nitrogen or urea, carbon dioxide/bicarbonate, chloride, creatinine, creatine phosphokinase, total protein, 
albumin, glucose, tr iglycerides, total cholesterol, phosphorus, and lactate dehydrogenase. At Day 1 of each cycle, biochemistry will include creatinine 
clearance (calculated using the Cockcroft and Gault 1976 formula).  
16  Urinalysis will include pH, specific gravity, p rotein, occult blood , glucose, ketones, nitrites  and bilirubin .  The urinalysis may be performed using a urine 
dipstick.  
17  Urine to be collected for testing of biomarkers suggestive of potential renal injury (aquaporin- 2, calbindin D28, and clusterin).  
18  On Day 1 of Cycles 1 a nd 2, a 12-lead ECG is to be performed before the start of the ADCT -301 infusion, at completion of infusion, and at 3 hours and 
24 hours (Day 2) after the end of infusion.  ECGs should occur within 10% of nominal time (e.g., 3 hours ± 18 minutes). 
19  See Section 13.1.2 of this Appendix for timing.   
20  Sample for assessment to be obtained 12 weeks (± 1 week) after last dose of ADCT -301, unless a new anticancer treatment has been initiated . 
21  Sampling for peripher al blood mononuclear cell (PBMC) subset analysis by Flow Cytometry in Cycles 1 and 2 , and at EOT; only in  Part 2.  
See Section  13.1.2 of this Appendix for sample timing.  
22  Patients to receive ADCT -301 intraven ously over 1 hours (± 15 minutes).  If ADCT- 301 is well tolerated after the first cycle, the infusion duration may be 
shortened to a 30-minutes  intravenous infusion for subsequent cycles at the Investigator’s discretion.  The IP administration window is ± 15 minutes.  
23  Dexamethasone prophylaxis (4 mg BID on Day -1, Day 1, and Day 2) should be administered, unless contraindicated. If Grade 2 or higher infusion- related 
hypersensitivity reactions are observed in a patient at any time during the study, this patient must receive prophylactic treatment with all subsequent dosing  
to reduce the risk of hypersensitivity reaction.  Prophylaxis for hypersen sitivity will supersede stipulations on  dexamethasone prophylaxis  
24  For all patients, collection of AEs and SAEs will continue for 12 weeks (84 days) after the last dose of study drug or initiation of new anticancer treatment .  
Any SAEs that occur more t han 84 days after the last dose of study drug do not need to be reported unless the Investigator considers the event to be re lated 
to study drug . 
25 To include  prescription or over -the-counter medication, herbal or naturopathic products within the 14 days prior to Day 1, throughout the study, and for 
30 days after last dose of study drug. 
26  After documentation of disease progression or start of new anti -cancer treatment, patients will be contacted by telephone approximately every 12 weeks for 
up to 12 months after the last dose of study drug to collect survival information.  
27 Information on anti- cancer treatment initiated after discontinuation of ADCT -301 to be recorded in the eCRF.  
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amend ment 9  
Date of Protocol: 4 January 2019                  Page 78  
13.1.2  Timing of ECG and Sample Collection for PK, ADA,  and PBMC s 
Assessment  Cycles 1 and 2  Cycle 3 – 
Progression  
EOT 
 Follow 
up  
3 mos 
after last 
infusion  
(±7 days)  Day 1  Day 2  Day 3  Day 5  Day 8 Day 15  Day 1  
Before 
start 
infusion  EOI 
(±10%)* 1 hr 
after 
EOI 
(±10%)  3 hrs 
after 
EOI 
(± 10%)  6 hrs 
after 
EOI 
(± 10%)  24 hrs 
after 
EOI 
(± 10%)  48 hrs 
after EOI  
(± 10%)  96 hrs 
after 
EOI 
(±1 day)  168 hrs 
after 
EOI 
(±2 
days)  336 hrs 
after 
EOI 
(±2 
days)  Before 
start 
infusion 
(± 10%)  EOI 
(±10%)  
PK X X X X X X X X X X X X X X1 
ADA2 X          X  X X1 
sCD25  X          X  X  
               
  
           
    
PBMC 
subsets 
(Study 
Part 2 
only) X   X   X X X X 
  X 
 
ECG  X X  X  X     X  X  
 
Abbreviations:  ADA, anti -drug antibody; EOI, end of infusion;  EOT, end of treatment;  ; hr, hour(s); mos, months; 
PK, pharmacokinetics;  PBMC, peripheral blood mononuclear cells . 
Note:  No sample collections for PK, ADA, , links at the screening visit.  
* Samples to be collected within 10% of nominal time point (e.g., 1 hr ± 6 min, 48 hrs ± 4.8 hrs) for first 48 hours.  
 
1 Sample to be obtained at Follow -up, unless a new anticancer treatment has been initiated.  
2 Patients who test positive for ADAs may be requested to supply additional ADA samples.  
 
 

ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 79 13.2 Appendix: Response Assessment of Hodgkin and Non- Hodgkin 
Lymphoma (Lugano Classification)  
Response Assessment of Hodgkin and Non -Hodgkin Lymphoma (Lugano Classification)  
Response / Site  PET- CT-Based Response  CT-Based Response  
Complete Complete metabolic response  Complete radiologic response   
(all of the following) 
Lymph nodes and 
extralymphatic sites  • Score 1, 2, or 3*  with or without a residual 
mass on 5PS** 
 
Note: Uptake may be greater than normal 
mediastinum and/or liver in Waldeyer’s ring 
or extranodal sites with high physiologic 
uptake or with activation within spleen or 
marrow (e.g., with chemotherapy or myeloid 
colony-stimulating factors).  In this 
circumstance, complete metabolic response may be inferred if uptake at sites of initial 
involvement is no greater than surrounding 
normal tissue even if the tissue has high 
physiologic uptake  • Target nodes/nodal masses must regress to≤ 1.5 cm in LD  
• No extralymphatic sites of disease  
Nonmeasured lesion • Not applicable  • Absent  
Organ enlargement  • Not applicable  • Regress to normal  
New lesions  • None • None 
Bone marrow  • No evidence of FDG -avid disease in marrow • Normal by morphology; if indeterminate, 
IHC negati ve 
Partial Partial metabolic response  Partial remission   
(all of the following) 
Lymph nodes and 
extralymphatic sites  • Score 4 or 5**  with reduced uptake 
compared with baseline and residual mass(es) of any size.  
• At interim, these findings suggest responding disease.  
• At end of treatment, these findings indicate 
residual disease.  • ≥50% decrease in SPD of up to 6 target 
measurable nodes and extranodal sites 
• When a lesion is too small to measure on 
CT, assign 5 mm × 5mm as the default 
value. 
• When no longer visible, 0 × 0 mm  
• For a node >5 mm × 5 mm, but smaller than normal, use actual measurement for calculation  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 80 Response Assessment of Hodgkin and Non -Hodgkin Lymphoma (Lugano Classification)  
Response / Site  PET- CT-Based Response  CT-Based Response  
Nonmeasured lesion • Not applicable  • Absent/normal, regressed, but no increase  
Organ enlargement  • Not applicable  • Spleen must have regressed by >50% in 
lengt h beyond normal  
New lesions  • None • None 
Bone marrow  • Residual uptake higher than uptake in normal marrow but reduced compared with 
baseline (diffuse uptake compatible with 
reactive changes from chemotherapy 
allowed) .  If there are persistent focal 
changes i n the marrow in the context of a 
nodal response, consideration should be 
given to further evaluation with MRI or 
biopsy or an interval scan  • No applicable  
No response or stable 
disease  No metabolic response  
 Stable disease  
Target nodes/nodal masses, extranodal 
lesions • Score 4 or 5 with no significant change in 
FDG update from baseline at interim or end of treatment  • <50% decrease from baseline in SPD of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive 
disease are met  
Nonmeasured lesions  • Not applicable  • No increase consistent with progression 
Organ enlargement  • Not applicable  • No increase consistent with progression 
New lesions  • None • None 
Bone marrow  • No change from baseline  • Not applicable  
Progressive disease Progressive metabolic disease  Progressive disease  
(requires at least 1 of the following) 
Individual t arget 
nodes/nodal masses  • Score 4 or 5 with an increase in intensity of 
uptake from baseline and/or  • PPD progression  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 81 Response Assessment of Hodgkin and Non -Hodgkin Lymphoma (Lugano Classification)  
Response / Site  PET- CT-Based Response  CT-Based Response  
Extranodal lesions  • New FDG-avid foci consistent with 
lymphoma at interim or end of treatment 
assessment  An individual node/lesion must be abnormal 
with:  
• LDi > 1.5 cm and  
• Increase by ≥50% from PPD nadir and  
• An increase in LDi or SDi from nadir  
0.5 cm for lesions ≤ 2 cm  
1.0 cm for lesions > 2 cm  
• In the setting of splenomegaly, the splenic 
length must increase by > 50% of the extent 
of its prior increase beyond baseline (e.g., a 
15-cm spleen must increase to > 16 cm) .  If 
no prior splenomegaly, must increase by at 
least 2 cm from baseline  
• New or recurrent spl enomegaly  
Nonmeasured lesions  • None • New or clear progression of preexisting nonmeasured lesions  
New lesions  • New FDG-avid foci consistent with lymphoma rather than another etiology (e.g. , 
infection, inflammation).  If uncertain 
regarding etiology of new lesions, biopsy or 
interval scan may be considered  • Regrowth of previously resolved lesions  
• A new node > 1.5 cm in any axis  
• A new extranodal site > 1.0 cm in any axis; if < 1.0 cm in any axis, its presence must be 
unequivocal and must be attributable to 
lymphoma  
• Assessable disease of any size 
unequivocally attributable to lymphoma  
Bone marrow  • New or recurrent FDG-avid foci  • New or recurrent involvement  
Abbreviations: 5PS, 5-point scale; CT, computed tomography; FDG, fluorodeoxyglucose; IHC, immunohistochemist ry; 
LDi, longest transverse diameter of a lesion; MRI, magnetic resonance imaging; PET, positron emission tomography; PPD, cross product of the LDi and perpendicular diameter; SDi, shortest axis perpendicular to the LDi; SPD, sum of the product 
of the perpendicular diameters for multiple lesions.  
 
* A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time of an interim 
scan.  However, in trials involving PET where de -escalation is investigated, it may be pr eferable to consider a score of 3 as 
inadequate response (to avoid undertreatment) .  Measured dominant lesions: Up to six of the largest dominant nodes, nodal 
masses, and extranodal lesions selected to be clearly measurable in two diameters .  Nodes should preferably be from 
disparate regions of the body and should include, where applicable, mediastinal and retroperitoneal areas .  Non-nodal 
lesions include those in solid organs (e.g. , liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted 
on palpation .  Nonmeasured lesions: Any disease not selected as measured, dominant disease and truly assessable disease 
should be considered not measured .  These sites include any nodes, nodal masses, and extranodal sites not selected as 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 82 Response Assessment of Hodgkin and Non -Hodgkin Lymphoma (Lugano Classification)  
Response / Site  PET- CT-Based Response  CT-Based Response  
dominant o r measurable or that do not meet the requirements for measurability but are still considered abnormal, as well as 
truly assessable disease, which is any site of suspected disease that would be difficult to follow quantitatively with 
measurement, including pleural effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other 
lesions that cannot be confirmed and followed by imaging.  In Waldeyer’s ring or in extranodal sites (e.g., GI tract, liver, 
bone marrow), FDG uptake may be greater than in the mediastinum with complete metabolic response, but should be no 
higher than surrounding normal physiologic uptake (e.g. , with marrow activation as a result of chemotherapy or myeloid 
growth factors).  
 
** PET 5PS: 1, no uptake above background; 2, uptake ≤ mediastinum; 3, uptake > mediastinum but ≤ liver; 4, uptake 
moderately > liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake unlikely to be related to 
lymphoma.  
 Reference:  Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz H, Lister  TA.  Recommendations for initial 
evaluation, staging, and response assessment of Hodgkin and Non- Hodgkin lymphoma:  The Lugano classification .  J Clin 
Onc 2014, 32(27):3059-3068 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 83 13.3 Appendix: Global Response Score  Grading Scales for Modified 
Severity -weighted Assessment Tool (mSWAT) for CTCL   
13.3.1  Skin Scoring  
13.3.1.1  Total Body Surface Area (TBSA) Involvement by Skin 
Disease  
The body is divided into 12 regions with pre -assigned percentage (%) total body surface area 
(TBSA) based on the burn literature .  The extent of skin disease in each region is quantified 
by using the patient’s palm to measure the %TBSA involvement within region: patient’s 
palm with 4 fingers (excluding the thumb) is 1% of TBSA .  Patient’s palm without fingers is 
0.5% of TBSA .  The patient’s palm with 4 fingers is traced on a transparency sheet at the 
baseline visit, using a permanent marker that will not rub off or smear.  The transparency of 
the patient’s palm should be used in all mSWAT assessments during the course of the 
clinical study .  The transparency will be labeled with the patient’s study ID number kept in 
the patient’s study file on site .  Using the baseline visit transparency of the patient’s palm, the  
Investigator will measure and record the %TBSA for each lesion type within each of the 
12 regions. 
13.3.1.2  Severity Weighting Factor 
The severity weighting factors will be the following: 
• 1= patch (flat erythema or erythema with mild infiltration)  
• 2=plaque (elevated erythema or erythema with moderate infiltration)  
• 4= tumor or ulceration (erythema with fissuring, ulceration or tumor) 
Patch is defined as abnormal skin not elevated from normal skin .  A plaque is defined as 
abnormal skin elevated from normal skin by < 5 mm.  A plaque elevated ≥ 5 mm is a tumor. 
13.3.1.3  Calculating Skin Scores  
The sum of %TBSA by lesion is derived by summing the %TBSA from all regions  affected 
by the lesion.  The sum of %TBSA across lesion types (patches, plaques and tumors) within 
each region cannot exceed the %TBSA for the region.  For example, the %TBSA for the 
head region is 7%.  The sum of %TBSA across lesion types from head can only range from 
0-7% .  The skin score subtotal by lesion type are derived by multiplying the sum of %TBSA 
for patches from all regions by 1, sum of %TBS of plaques from all regions by 2, and the sum of %TBSA of tumors or ulcers from all regions by 4.  The skin score total is derived 
from summing the skin score subtotals for patches, plaques and tumors or ulcers . 
The skin score total is dimensionless with a scale of 0 to 400 . 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 84 %TBSA for Each Lesion Type Within Each of the 12 Regions  
Region  Percentage TBSA 
for the region  Percentage TBSA 
patch (or flat 
erythema)  Percentage TBSA 
plaque (or 
elevated/indurated 
erythema)  Percentage TBSA 
tumor/ulceration 
(or erythema 
w/fissuring, 
ulceration  
Head  7    
Neck  2    
Anterior Trunk  13    
Posterior Trunk  13    
Buttocks  5    
Genitalia  1    
Upper Arms  8    
Forearms  6    
Hands  5    
Thighs  19    
Lower Leg  14    
Feet 7    
%BSA by category  100    
Severity Weighting 
factor   ×1 ×2 ×4 
Skin Score subtotal      
Abbreviations : TBSA, total body surface area;  BSA, body surface area  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 85 13.3.1.4  Response Definitions  
Responses will be determined by the criteria described in the table below .  Progression of 
disease while on treatment should be confirmed by a second assessment 1  to 4 weeks later so 
that patients who experience a temporary flare of disease due to skin infection or other 
intercurrent illnesses are not removed from the study prematurely.  
 
Response  Description  
Skin   
Complete 
Response (CR)  No e vidence  of disease;  100% clearance of skin lesions.  
Partial Response 
(PR)  ≥50% decrea se in skin scores compared  to baseline and improve ment is maintained  for a 
minimum of 4 weeks  
Stable Disease 
(SD)  < 50% decrease  in skin scores co mpared  to baseline  
Progressive 
Disease (PD)  ≥ 25% in crease in skin scores co mpared  to baseline while the patient  is actively  taking  the 
study  drug, 
or new tumor(s) ≥ 1  cm diameter in skin disease only patient , 
or ≥ 50% increase  in the sum of the products  of the  greatest  diameters  of pathologically  
positive  lymph nodes (should be docu mented  by biopsy) compared  to baseline  while  the 
patient is actively  taking  the study  drug.  
Relapse  Any disease recurrence in those with complete response.  
Lymph Nodes (peripheral and central)  
CR All lymph nodes are now  ≤ 1.5 cm in greatest transverse (long axis) diamete r by method 
used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph 
nodes that were N 3 classification and ≤ 1.5 cm in their long axis and > 1 cm in their short 
axis at baseline, must now be ≤ 1 cm in their short axis or b iopsy negative for lymphoma  
PR Cumulative reduction > 50% of the SPD of each abnormal lymph node at baseline and no 
new lymph node > 1.5 cm in the diameter of the long axis or >1.0 cm in the diameter of the 
short axis if the long axis is 1 -1.5 cm diamete r  
SD Fails to attain criteria for CR, PR, or PD 
PD ≥ 50% increase in SPD from baseline of lymph nodes  
or Any new node > 1.5 cm in the long axis or > 1 cm in the short axis if 1 -1.5 cm in the 
long axis that is proven to be N3 histologically  
or Loss of response: > 50% increase from nadir in SPD of  lymph no des in those with PR  
Relapse  Any new lymph node > 1.5 cm in the long axis in those with CR proven to be N 3 
histologically.  
Viscera   
CR Liver or spleen or any organ considered involved at baseline should not be enlarged on 
physical exam and should be considered normal by imaging; no nodules should be present on imaging of liver or spleen; any post treatment mass must be determined by biopsy to be 
negative for lymphoma  
PR ≥ 50% regression in any splenic or liver nodules, or in measurable  disease (SPD) in any 
organs abnormal at baseline; no increase in size of liver or spleen and no new sites of 
involvement  
SD Fails to attain criteria for CR, PR, or PD  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 86 Response  Description  
PD >50% increase in size (SPD) of any organs involved at baseline  
or New organ involvement  
or Loss of response: >50% increase from nadir in the size (SPD) of any previous organ 
involvement in those with PR  
Relapse  New organ involvement in those with CR.  
Blood   
CR (a)  B0: Absence of significant blood involvement, <5% of peripheral  blood lymphocytes are 
atypical (Sézary) cells  
PR (b)  >50% decrease in quantitative measurements of blood tumor burden from baseline in those 
with high tumor burden at baseline (B 2) 
SD Fails to a ttain criteria for CR, PR, or PD  
PD B0 to B2  
or >50% increase from Baseline and at least 5,000 neoplastic cells/µL,  
or >50% increase from nadir and at least 5,000 neoplastic cells/µL for those with OR who 
were originally B2 at baseline.  
Relapse  Increase of neoplastic blood lymphocytes to ≥ B1 in those with CR  
SPD = sum of the maximum linear dimension (major axis) x longest perpendicular dimension (minor axis)  
 
13.3.2  Global Response Score 
The individual component scores for skin, nodes, blood, and viscera are i ncorporated into the 
definition of the Global Response Score (see table below). 
Global Score  Definition  Skin  Nodes  Blood  Viscera  
Complete 
Response (CR)  Complete disappearance of all 
clinical evidence of disease  CR All categories have CR/noninvolved  (NI) 
Partial 
Response (PR)  Regression of measurable disease  CR All categories do no t have a CR/NI and no 
category has a PD  
PR No category has a PD and if any category 
involved at baseline, at least one has a CR or 
PR 
Stable Disease (SD) Failure to attain CR, PR, or PD representative of all disease  PR 
No category has a PD and if any category 
involved at baseline, no CR or PR in any  
SD CR/NI, PR, SD in any category and no 
category has a PD  
Progressive 
Disease (PD)  Progressive disease  PD in any category  
Relapse Recurrence disease in prior 
CR  Relapse in any category  
References:  
Olsen EA, S Whittaker, Kim  YH, Duvic  M, Prince  HM, Lessin  SR, et al. Clinical end points and response 
criteria in mycosis fungoides and Sézary Syndrome:  a consensus statement of t he International Society for 
Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma 
Task Force of the European Organisation for Research and Treatment of Cancer.  J Clin Onc 2011; 
29(18):2598- 2607.  
Stevens SR, Ke M S, Parry EJ, Mark J, Cooper KD .  Quantifying skin disease burden in mycosis fungoides -type 
cutaneous T -cell lymphomas:  the severity -weighted assessment tool (SWAT).  Arch Dermatol  2002; 138:42 -48. 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 87 13.4 Appendix: CTCAE Immune System Hypersensitivity Grades  
 
 
Adverse Event  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Allergic reaction  Transient 
flushing or rash, 
drug fever 
<38°C 
(<100.4°F); 
intervention not 
indicated  Intervention or 
infusion 
interruption 
indicated; 
responds 
promptly to 
symptomatic 
treatment ( e.g., 
antihistamines, 
NSAIDS, 
narcotics); 
prophylactic 
medications 
indicated for 
≤24  hours Prolonged ( e.g., 
not rapidly 
responsive to 
symptomatic 
medication 
and/or brief 
interruption of 
infusion); 
recurrence of 
symptoms 
following initial 
improvement; 
hospitalization 
indicated for 
clinical sequelae 
(e.g., renal 
impairment, 
pulmonary 
infiltrates)  Life-threatening 
consequences;  
urgent intervention 
indicated  Death  
Definition: A disorder characterized by an adverse local or general response from exposure to an allerg en. 
Anaphylaxis  - - Symptomatic 
bronchospasm, 
with or without 
urticaria; 
parenteral 
intervention 
indicated; allergy -
related 
edema/angioedem
a; hypotension  Life-threatening 
consequences;  
urgent 
intervention 
indicated  Death  
Definition: A disorder characteri zed by an acute inflammatory reaction resulting from the release of histamine 
and histamine -like substances from mast cells, causing a hypersensitivity immune response .  Clinically, it 
presents with breathing difficulty, dizziness, hypotension, cyanosis , and loss of consciousness and may lead to 
death.  
Autoimmune 
disorder  Asymptomatic; 
serologic or 
other evidence 
of autoimmune 
reaction, with 
normal organ 
function; 
intervention not 
indicated  Evidence of 
autoimmune 
reaction 
involving a non -
essential organ 
or function ( e.g., 
hypothyroidism)  Autoimmune 
reactions 
involving major 
organ ( e.g., colitis, 
anemia, 
myocarditis, 
kidney) Life-threatening 
consequences;  
urgent intervention 
indicated  Death  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 88 Adverse Event  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Definition: A disorder resulting from loss of function or tissue de struction of an organ or multiple organs, 
arising from humoral or cellular immune responses of the individual to his own tissue constituents.  
Cytokine release 
syndrome  Mild 
reaction; 
infusion 
interruption 
not 
indicated; 
intervention 
not 
indicated  Therapy or 
infusion 
interruption 
indicated but 
responds 
promptly to 
symptomatic 
treatment ( e.g., 
antihistamines, 
NSAIDS, 
narcotics, 
intravenous  
fluids); 
prophylactic 
medications 
indicated for ≤24  
hours Prolonged ( e.g., 
not rapidly 
responsive to 
symptomatic 
medicat ion 
and/or brief 
interruption of 
infusion); 
recurrence of 
symptoms 
following initial 
improvement; 
hospitalization 
indicated for 
clinical sequelae 
(e.g., renal 
impairment, 
pulmonary 
infiltrates)  Life-threatening 
consequences; 
pressor or 
ventilatory 
support indicated  Death  
Definition: A disorder characterized by nausea, headache, tachycardia, hypotension, rash, and shortness of 
breath; it is caused by the release of cytokines from the cells.  
Serum sickness  Asymptomatic; 
clinical or 
diagnostic 
observations 
only; 
intervention 
not indicated  Moderate 
arthralgia; fever, 
rash, urticaria, 
antihistamines 
indicated  Severe 
arthralgia or 
arthritis; 
extensive 
rash; steroids 
or intravenous 
fluids 
indicated  Life-threatening 
consequences; 
pressor or 
ventilatory 
support indicated  Death  
Definition: A disorder characterized by a delayed -type hypersensitivity reaction to foreign proteins derived 
from an animal serum .  It occurs approximately 66 to 21 days following the administration of the foreign 
antigen .  Symptoms include f ever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked 
discomfort , and dyspnea.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 89 Adverse Event  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Immune 
system 
disorders - 
Other, specify  Asymptomatic or 
mild symptoms; 
clinical or 
diagnostic 
observations 
only; 
intervention not 
indicated  Moderate; 
minimal, local 
or noninvasive 
intervention 
indicated; 
limiting 
age-appropriat
e instrumental 
ADL  Severe or 
medically 
significant but 
not immediately 
life-threatening; 
hospitalization 
or prolongation 
of existing 
hospitalization 
indicated; 
disabling;  
limiting sel f-
care ADL  Life-threatening 
consequences;  
urgent 
intervention 
indicated  Death  
 
Abbreviations: ADL, Activities of daily living; NSAIDs, non -steroidal anti- inflammatory drugs.  
Adapted f rom CTCAE 4.0 – June 14, 2010, Immune system disorders . 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 90 13.5 Appendix: Dose  Escalation Scheme Report 
13.5.1  Overview  
A primary objective of the dose escalation portion of the study is to estimate an MTD .  
The MTD will be the highest safe dose that has at least a 60% probability that the dose 
limiting toxicity (DLT) rate is < 30%.  The D LT observation period is 1 cycle .  
Dose escalation will begin with the 3  µg/kg starting dose ( Dose Level 1 ).  There will be 
33 dose levels including all dose levels from : 
• 0.003 to 0.02 mg/kg in increments of 0.001 
• 0.02 to 0.05 mg/kg in increments of 0.005 
• 0.05 to 0.10 mg/kg in increments of 0.01 
• 0.10 to 0.30 mg/kg in increments of 0.05 
Dose escalation will be conducted according to a continual reassessment method (CRM) .  
Non-DLT toxicity events (i.e. Grade  2 or higher toxicities) will inform the probability  of 
DLT at each dose level .  Dose escalation is also conducted according to a set of rules that 
govern entry into the study and assignment of dose level .  These rules allow that untried dose 
levels may be skipped .  The trial is continuously monitored for safety and early stopping for 
successfully identifying the MTD.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 91 13.5.2  Continual Reassessment Method  
Dose escalation in this study will be conducted using the CRM .  For each dose , d = 1,….,33, 
we model the ordinal outcome of no toxicity event, non- DLT (i.e. Grade  2) toxicity event, or 
a DLT.  
We model the log odds of a DLT, 
 
with a two -parameter model  
 
We model the log odd-odds of a non-DLT toxicity  
 
as related to DLTs by including an additive ter m, γ, which must be > 0,  
. 
We place the following independent prior distributions on the parameters.  
α ~ N( –3, 62) 
β ~ N(8, 202) 
γ ~ N+(3, 62) 
This parameterization imposes that Grade  2 or higher  toxicities (which include DLTs) will 
occur more frequently than DLTs.  We use “pseudo -prior” weighting to impose a prior 
expectation of the rate of DLTs that helps shape the correlation of the parameters.  
We assume one observation each of three doses.  We place one observation with 0% DLT on 
the 0.003 mg/kg dose, with 30% DLT on the on the 0.10  mg/kg dose, and with 60% DLT on 
the 0.20 mg /kg dose.  
After each patient is treated and assessed for non -DLT toxicity or DLT, the distributions of 
all parameters are updated and the MTD is estimated based on the posterior probability of 
DLT at each dose.  
Additionally, we define a dose as safe if there is at least a 60% probability that the DLT rate 
is < 30%,  
Pr(πd < 30%) > 60%. 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 92 Patients cannot be assigned to a dose that is not safe by this definition .  
13.5.3  Dose Escalation Rules  
Dose escalation begins with enrollment of patients on the 0.003 mg/kg dose .  The queue 
refers to the number of patients that ha ve been allocated to doses, but have not yet completed 
the observation period.  For safety purposes we want to keep the queue size moderate to 
prevent large numbers of patients being enrolled at any one time.  Until 4 patients have 
complete DLT information the queue maximum is 2.  After 4 patients have complete DLT 
information , the queue increases to 3 .  Patients cannot be enrolled for dose escalation if the 
queue maximum has been reached.  
13.5.3.1  Starting Dose and Entry into the Study 
Dose escalation begins with enrollment of patients on the 0.003 mg/kg dose (dose escalation 
will be conducted according to a CRM, as described in Appendix 13.5).   
The queue refers to the number of patients that have been allocated to doses, but have not yet 
completed the observation period.  For safety purposes we want to keep the queue size 
moderate to prevent large numbers of patients being enrolled at any one time . 
Until 4 patients have complete DLT information the queue maximum is 2.  After 4 patients 
have complete DLT information the queue increases to 3.  Patients cannot be enrolled for dose escalation if the queue maximum has been reached.  
13.5.3.2  Assignment of Dose Level 
The dose -toxicity model will be used to assign patients to doses .  However, assignment of 
dose level is also governed by rules that govern the speed of dose escalation and rules that determine if untried dose levels may be skipped.  
There must be complete DLT information through the first cycle ( 3 weeks) on at least 
2 patie nts in order to escalate .  When the dose is escalated, the dose level may increase by 
100% as long as no toxic ity events are observed .  Once  a non-DLT toxicity is observed, the 
dose may only be increased by 67%; and once a DLT is observed , the dose may onl y increase 
by 50%.  In addition, the dose may never increase by more than 100% or by more than an 
absolute value of 1) 0.02 mg/kg at dose levels below 0.10 or 2) 0.10 mg/kg for dose levels 
between 0.10 and 0.30. The increase in dose level is always constra ined by the dose -toxicity model.  The dose may 
never escalate to a dose that is considered unsafe.    
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 93 13.5.4  Interim Monitoring  
The trial is continuously monitored for safety and for success in identifying the MTD .  
If dose escalation is not stopped for either sa fety or success in identifying the MTD it will 
continue to enroll to the maximum sample size.  
13.5.4.1  Safety Monitoring  
The lowest dose (0.003 mg/kg) will be considered unsafe if it has a probability < 25% of a 
DLT rate < 30%.  The trial will stop, and no MTD found, if the lowest dose is considered 
unsafe (hence all doses are considered unsafe).  
13.5.4.2  Success in Identifying the MTD  
Dose escalation may be stopped early when sufficient information around the MTD has been 
obtained.  We characterize this by having a suffici ent number of patients at and around the 
MTD .  We require at least 3 patients with complete inform ation at the MTD and at least 
6 patients with complete information within a certain interval around the MTD .  If the MTD 
is 0.010 mg/kg or lower, we require 6 patients at the MTD .  If the MTD is 0.011 mg/kg or 
greater , we require a total of 6 patients between the MTD and the dose level below .  
13.5.5  Operating Characteristics  
To evaluate how the dose escalation design performs, we simulated the study considering different dose -toxicity scenarios.  We show operating characteristics of the trial based on 
1,000 simulations per scenario.  For each scenario we plot the mean sample size and 
cumulative probability of MTD across the 33 dose levels including all dose levels  from: 
• 0.003 to 0.02 mg/kg in increments of 0.001 
• 0.02 to 0.05 mg/kg in increments of 0.005 
• 0.05 to 0.10 mg/kg in increments of 0.01 
• 0.10 to 0.30 mg/kg in increments of 0.05   
The true DLT scenario is shown for reference along with a line indicating a 30% DLT rate.  
We further summarize the performance of the dose escalation design by showing the mean sample size and the 10%, 20%, 50%, 80%, and 90% quantiles of the cumulative MTD curve.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 94  
13.5.5.1  All Doses Safe 
 
 
 
  Quantile of Cumulative MTD Selection  
True  
MTD  Mean  
N 10% 20% 50% 80% 90% 
0.3 38 0.25 0.30 0.30 0.30 0.30 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 95  
 
13.5.5.2  MTD is the H ighest Dose (0.30 mg/kg) 
 
 
 
  Quantile of Cumulative MTD Selection  
True  
MTD  Mean 
N 10% 20% 50% 80% 90% 
0.30 38.3 0.10 0.15 0.20 0.30 0.30 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 96 13.5.5.3  MTD is a Middle Dose (0.15 mg/kg) 
 
 
 
  Quantile of Cumulative MTD Selection  
True  
MTD  Mean 
N 10% 20% 50% 80% 90% 
0.15 35.6 0.10 0.10 0.15 0.15 0.20 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 97 13.5.5.4  MTD is a M iddle Dose (0.10 mg/kg) 
 
 
 
  Quantile of Cumulative MTD Selection  
True  
MTD  Mean 
N 10% 20% 50% 80% 90% 
0.1 34.9 0.07 0.09 0.10 0.10 0.15 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 98 13.5.5.5  MTD is a Low D ose (0.05 mg/kg) 
 
 
 
  Quantile of Cumulative MTD Selection  
True  
MTD  Mean 
N 10% 20% 50% 80% 90% 
0.05 34.2 0.04 0.05 0.06 0.07 0.08 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 99 13.5.5.6  MTD is a Low D ose (0.02 mg/kg) 
 
 
 
  Quantile of Cumulative MTD Selection  
True  
MTD  Mean 
N 10% 20% 50% 80% 90% 
0.02 32.6 0.013 0.018 0.020 0.025 0.03 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 100 13.5.5.7  No Doses Safe 
In this scenario, there is a 61% probability of stopping early for safety.  The lowest dose is 
selected as the MTD with 37% probability. 
 
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 101 13.6 Appendix: Clinical Case Definitions: Level 1 of Di agnostic Certainty 
for Guillain- Barré  Syndrome  
• Bilateral AND flaccid weakness of the limbs1, 2, 3 
AND  
• Decreased or absent deep tendon reflexes in weak limbs4 
AND  
• Monophasic illness pattern5 AND interval between onset and nadir of weakness 
between 12 h and 28 days AND subsequent clinical plateau6 
AND  
• Electrophysiologic findings consistent with GBS7 
AND  
• Cytoalbuminologic dissociation (i.e., elevation of CSF protein level above laboratory 
normal value AND CSF total white cell count <50 cells/ µL)8 
AND  
• Absence of an identified alternative diagnosis for weakness9. 
Reference:  Sejvar 201113 
1 Weakness is usually, but not always, symmetric in nature, and usually has a pattern of progression from legs to 
arms (ascending). H owever, other patterns of  progression may occur (e.g., beginning in the arms). The degree 
of weakness can  range from mild to moderate to severe, i.e., complete paralysis.  
2 Respiratory or cranial nerve -innervated muscles may also be involved.  
3 It is impor tant that strength be assessed in a manner that takes into account  subject age, sex, and level of 
functioning.  
4 Decreased or absent tendon reflexes may also be seen in limbs without weakness. However, to meet case 
definition criteria, decreased or absent tendon reflexes  must be observed in weak limbs.  
5 Fluctuations in level of weakness, before reaching nadir, or during the plateau or  improvement phases, occur 
in some  cases, usually associated with the use of disease- modifying  therapies. Such fluctuations usually occur 
within the first 9 weeks after  onset and are followed by eventual improvement.  
6 The eventual outcome is either stabilization at nadir OR subsequent improvement  OR death.  
7 Electrophysiologic patterns consistent with polyneuropathy of the types  described for GBS.  
Electrophysiologic studies performed sooner than 7 days  after weakness onset may be normal and should thus 
be repeated at a later time if  possible, and “normal” studies  may occur in otherwise typical cases of GBS. 
However, cases with persistently “normal” studies will not meet Level 1 criteria.  
8 CSF (cerebrospinal fluid) protein concentrations should be elevated above what  is considered normal 
reference values for the testing laboratory. CSF may be “normal” in otherwise typical cases of GBS; this is 
particularly true within the first week  of illness. However, cases with persistently “normal” CSF, or CSF with 
≥50 WBC, will  not meet Level 1 criteria.  
9 If an alternative diagnosis explaining flaccid weakness/paralysis is present  a diagnosis of Guillain –Barré 
syndrome is excluded. However, in  many, if not most cases, a comprehensive documentation of testing for 
various other  etiologies will either be incomplete or unavailable. Thes e case definitions are provided to give 
guidance in the absence of detailed information on investigations for  altern ative etiologies of flaccid paralysis.  
ADC Therapeutics  ADCT -301 
ADCT -301-001 Protocol  Amendment 9 
Date of Protocol: 4 January 2019            Page 102  
13.7 Appendix: Guillain –Barré Syndrome Disability S cale 
Score  Description  
0 Healthy  
1 Minor symptoms or signs of neuropathy but capable of manual work/capable of 
running 
2 Able to walk without support of a stick (5m ac ross an open space) but incapable 
of manual work/running 
3 Able to walk with a stick, appliance, or support (5m across an open space)  
4 Confined to bed or chair bound  
5 Requiring assisted ventilation (for any part of the day or night)  
6 Death  
Reference: Sejvar 201113 
 